Alliance HealthCare Services (AIQ) 10-Q 7 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 07, 2015
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	Alliance HealthCare Services, Inc
Entity Central Index Key	817,135
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		10,750,624

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 43,399	$ 33,033
Accounts receivable, net of allowance for doubtful accounts of $4,055 in 2014 and $3,700 in 2015	66,466	62,503
Deferred income taxes	16,834	16,834
Prepaid expenses	13,271	12,527
Other receivables	2,809	5,686
Total current assets	142,779	130,583
Equipment, at cost	851,783	827,638
Less accumulated depreciation	(685,200)	(678,291)
Equipment, net	166,583	149,347
Goodwill	86,475	63,864
Other intangible assets, net	129,611	115,930
Deferred financing costs, net	7,454	8,119
Other assets	33,514	33,042
Total assets	566,416	500,885
Current liabilities:
Accounts payable	15,158	12,109
Accrued compensation and related expenses	21,295	19,808
Accrued interest payable	3,123	3,154
Income taxes payable	149	0
Other accrued liabilities	30,471	26,542
Current portion of long-term debt	22,484	15,512
Total current liabilities	92,680	77,125
Long-term debt, net of current portion	520,664	491,777
Other liabilities	6,502	6,623
Deferred income taxes	36,143	36,840
Total liabilities	$ 655,989	$ 612,365
Commitments and contingencies
Stockholders’ deficit:
Common stock	$ 107	$ 107
Treasury stock	(3,138)	(3,138)
Additional paid-in capital	28,415	27,653
Accumulated comprehensive loss	(492)	(351)
Accumulated deficit	(194,301)	(194,091)
Total stockholders’ deficit attributable to Alliance HealthCare Services, Inc.	(169,409)	(169,820)
Noncontrolling interest	79,836	58,340
Total stockholders’ deficit	(89,573)	(111,480)
Total liabilities and stockholders’ deficit	$ 566,416	$ 500,885

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 3,700	$ 4,055

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues	$ 118,504	$ 111,238	$ 227,933	$ 216,603
Costs and expenses:
Cost of revenues, excluding depreciation and amortization	67,485	59,627	129,371	116,567
Selling, general and administrative expenses	20,800	19,384	41,755	38,123
Transaction costs	1,113	937	1,532	939
Severance and related costs	195	1,727	454	1,860
Impairment charges	6,670	236	6,746	236
Depreciation expense	12,072	14,274	23,705	30,069
Amortization expense	2,495	1,957	4,530	3,909
Interest expense and other, net	6,904	6,124	12,922	12,362
Other (income) expense, net	486	(408)	127	(331)
Total costs and expenses	118,220	103,858	221,142	203,734
Income before income taxes, earnings from unconsolidated investees, and noncontrolling interest	284	7,380	6,791	12,869
Income tax expense (benefit)	(1,366)	1,802	206	3,309
Earnings from unconsolidated investees	(1,292)	(1,242)	(2,455)	(2,240)
Net income	2,942	6,820	9,040	11,800
Less: Net income attributable to noncontrolling interest	(4,903)	(4,036)	(9,250)	(7,085)
Net income (loss) attributable to Alliance HealthCare Services, Inc.	(1,961)	2,784	(210)	4,715
Comprehensive income (loss), net of taxes:
Net income (loss) attributable to Alliance HealthCare Services, Inc.	(1,961)	2,784	(210)	4,715
Unrealized loss on hedging transactions, net of taxes	(13)	(235)	(141)	(215)
Comprehensive income (loss), net of taxes	$ (1,974)	$ 2,549	$ (351)	$ 4,500
Income (loss) per common share attributable to Alliance HealthCare Services, Inc.:
Basic (dollars per share)	$ (0.18)	$ 0.26	$ (0.02)	$ 0.44
Diluted (dollars per share)	$ (0.18)	$ 0.26	$ (0.02)	$ 0.43
Weighted-average number of shares of common stock and common stock equivalents:
Basic (shares)	10,715	10,671	10,714	10,669
Diluted (shares)	10,836	10,854	10,839	10,872

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities:
Net income	$ 9,040	$ 11,800
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts	1,054	1,146
Share-based payment	819	710
Depreciation and amortization	28,235	33,978
Amortization of deferred financing costs	2,098	948
Accretion of discount on long-term debt	232	222
Adjustment of derivatives to fair value	98	355
Distributions greater than undistributed earnings from investees	189	224
Deferred income taxes	(697)	(2,655)
Gain on sale of assets	(406)	(185)
Impairment charges	6,746	236
Excess tax benefit from share-based payment arrangements	5	(515)
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable	(577)	(1,566)
Prepaid expenses	(1,499)	1,109
Other receivables	(242)	62
Other assets	534	(26)
Accounts payable	627	(2,485)
Accrued compensation and related expenses	340	(3,473)
Accrued interest payable	(31)	1,465
Income taxes payable	131	6
Other accrued liabilities	964	1,488
Net cash provided by operating activities	47,660	42,844
Investing activities:
Equipment purchases	(26,382)	(13,256)
Decrease in deposits on equipment	(9,935)	(3,628)
Acquisitions, net of cash received	(24,061)	(1,529)
Proceeds from sale of assets	520	570
Net cash used in investing activities	(59,858)	(17,843)
Financing activities:
Proceeds from equipment debt	15,691	0
Principal payments on equipment debt	(4,639)	(5,450)
Proceeds from term loan facility	29,850	0
Principal payments on term loan facility	(7,351)	(2,450)
Principal payments on revolving loan facility	(28,000)	(32,000)
Proceeds from revolving loan facility	26,000	18,000
Payments of debt issuance costs	(654)	0
Noncontrolling interest in subsidiaries	(8,353)	(6,573)
Equity purchase of noncontrolling interest	0	(691)
Excess tax benefit from share-based payment arrangements	(5)	515
Proceeds from shared-based payment arrangements	25	403
Purchase of treasury stock	0	(140)
Net cash (used in) provided by financing activities	22,564	(28,386)
Net (decrease) increase in cash and cash equivalents	10,366	(3,385)
Cash and cash equivalents, beginning of period	33,033	34,702
Cash and cash equivalents, end of period	43,399	31,317
Supplemental disclosure of cash flow information:
Interest paid	11,110	9,877
Income taxes paid, net of refunds	(146)	4,991
Supplemental disclosure of non-cash investing and financing activities:
Capital lease obligations related to the purchase of equipment	1,294	0
Unrealized loss on hedging transactions, net of taxes	(141)	(215)
Equipment purchases in accounts payable	2,477	666
Noncontrolling interest assumed in connection with acquisitions	20,598	0
Adjustment to equity of noncontrolling interest	0	1,700
Extinguishment of note receivable	$ 3,071	$ 0

Basis of Presentation, Principl

Basis of Presentation, Principles of Consolidation, and Use of Estimates	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation, Principles of Consolidation, and Use of Estimates	Basis of Presentation, Principles of Consolidation, and Use of Estimates Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the quarter and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 . The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2014 . Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company records noncontrolling interest related to its consolidated subsidiaries which are not wholly owned. Investments in non-consolidated investees are accounted for under the equity method. Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Transactions

Transactions	6 Months Ended
	Jun. 30, 2015
Business Combinations, Restructuring and Related Activities [Abstract]
Transactions	Transactions Restructuring Plan During the six months ended June 30, 2015 , the Company recorded $491 related to restructuring charges, of which the Company recorded $95 in selling, general and administrative expenses, and $396 in cost of revenues, excluding depreciation and amortization. The Company also recorded $454 in severance and related costs during the six months ended June 30, 2015 . During the six months ended June 30, 2014 , the Company recorded $2,455 related to restructuring charges, of which the Company recorded $1,640 in selling, general and administrative expenses and $815 in cost of revenues, excluding depreciation and amortization. The Company also recorded $1,860 in severance and related costs, primarily as a result of the departure of one of its executive officers during the second quarter of 2014. Acquisition of The Pain Center of Arizona On February 17, 2015, the Company purchased approximately 59% membership interest in The Pain Center of Arizona ("TPC"), a comprehensive full-time pain management medical practice with 12 locations within the state of Arizona. The acquisition took place in two stages: a purchase of a 60.0% membership interest in TPC by the Company, and a 50.0% membership interest in Medical Practice Innovations, Inc. (“MPI”), followed by a transfer of MPI assets to TPC. The MPI transaction diluted the ownership interests of TPC, with the Company retaining approximately 59% membership interest in TPC. The purchase price consisted of $23,630 in cash, net of $691 cash acquired, and net of extinguishment of $3,071 of related-party notes receivable. The Company financed this acquisition using the revolving line of credit. The following table summarizes recognized amounts of identifiable assets acquired and liabilities assumed at the acquisition date: Cash received $ 691 Accounts receivable, net 4,440 Equipment, net 3,346 Other assets 416 Goodwill 22,611 Identifiable intangible assets 24,600 Debt (2,781 ) Other liabilities (3,532 ) Noncontrolling interest (20,598 ) Total consideration $ 29,193 As a result of this acquisition, the Company recorded goodwill of $22,611 . In addition, the Company recorded intangible assets of $24,600 , of which $13,500 was assigned to physician referral network and $11,100 was assigned to trademarks, which are all being amortized over 20 years . The Company recorded the intangible assets at fair value at the acquisition date, which was estimated using the income approach. A portion of the recorded goodwill and intangible assets is being amortized over 15 years for tax purposes. The fair value of noncontrolling interest related to this transaction was $20,598 as of the acquisition date. To estimate the fair value of noncontrolling interest, the Company used the implied fair value based on the Company's ownership percentage. The results for the quarter and six months ended June 30, 2015 included $8,167 and $12,023 of revenue, respectively, and $20 and $291 of net income, respectively, generated by TPC. The historical results of operations of the business acquired during the six months ended June 30, 2015 are not material, and accordingly, pro forma financial information is not presented. The values assigned to the various assets and liabilities acquired in this transaction are preliminary and may be subject to adjustment as the calculation of their respective fair values could be subject to change. The agreement includes contingent consideration arrangements, which are based on performance of the 12 -month period following the transaction date. The fair value of these contingent consideration arrangements of $1,800 was estimated using probability-adjusted performance estimates as of June 30, 2015.

Share-Based Payment

Share-Based Payment	6 Months Ended
	Jun. 30, 2015
Share-based Compensation [Abstract]
Share-Based Payment	Share-Based Payment The Company has adopted ASC 718, “Compensation—Stock Compensation,” and has elected to follow the alternative transition method as described in ASC 718 for computing its beginning additional paid-in capital pool. In addition, the Company treats the tax deductions from stock options as being realized when they reduce taxes payable in accordance with the principles and timing under the relevant tax law. Stock Option Plans and Awards In November 1999, the Company adopted an employee stock option plan (as amended and restated, the “1999 Equity Plan”) pursuant to which options and awards with respect to a total of 2,205,000 shares have become available for grant. As of June 30, 2015 , a total of 477,060 shares remained available for grant under the 1999 Equity Plan. Options are granted with exercise prices equal to the fair value of the Company’s common stock at the date of grant. All options have 10 -year terms. Options granted after January 1, 2008 are typically time-based and vest in equal tranches over three or four years , subject to continued service. During the year ended December 31, 2014 and the six months ended June 30, 2015 there were no options in which vesting was accelerated. Prior to January 1, 2008, stock options granted under the 1999 Equity Plan to employees were all time-vesting options which had 5% vesting in the first year, 20% vesting in the second year and 25% vesting in years three through five. The Company uses the Black-Scholes option pricing model to value the compensation expense associated with share-based payment awards. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the assumptions noted in the table below. In addition, forfeitures are estimated when recognizing compensation expense and the estimate of forfeitures is adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and impact the amount of compensation expense to be recognized in future periods. The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards: Six months ended June 30, 2014 2015 Risk free interest rate 1.83 % 1.65 % Expected dividend yield — % — % Expected stock price volatility 66.3 % 65.2 % Average expected life (in years) 6.00 6.00 The Company calculates its stock price volatility and average expected life based on its own historical data. The risk free interest rates are based on the United States Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option or award. The following table summarizes the Company’s stock option activity: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2015 633,898 $ 21.39 Granted 83,514 23.91 Exercised (2,515 ) 10.12 Canceled (28,117 ) 55.81 Outstanding at June 30, 2015 686,780 $ 20.35 6.02 $ 3,482 Vested and expected to vest in the future at June 30, 2015 662,238 $ 20.18 5.94 $ 3,476 Exercisable at June 30, 2015 488,809 $ 18.14 5.17 $ 3,393 The weighted average grant date fair value of options granted during the six months ended June 30, 2014 and 2015 was $17.56 per share and $14.25 per share, respectively. Total stock options exercised was 2,515 during the six months ended June 30, 2015 . There were 67,657 options exercised during the six months ended June 30, 2014 . The following table summarizes the Company’s unvested stock option activity: Shares Weighted-Average Grant-Date Fair Value Unvested at January 1, 2015 197,899 $ 12.13 Granted 83,514 14.25 Vested (78,825 ) 6.08 Canceled (4,617 ) 15.35 Unvested at June 30, 2015 197,971 $ 15.40 At June 30, 2015 , the total unrecognized fair value share-based payment related to unvested stock options granted to employees was $2,046 , which is expected to be recognized over a remaining weighted-average period of 2.07 years. The valuation model applied in this calculation utilizes highly subjective assumptions that could potentially change over time, including the expected forfeiture rate and performance targets. Therefore, the amount of unrecognized share-based payment noted above does not necessarily represent the value that will ultimately be realized by the Company in the consolidated statements of operations and comprehensive income. The total fair value of shares vested during the six months ended June 30, 2014 and 2015 was $469 and $479 , respectively. Stock Awards The 1999 Equity Plan, as amended and restated, permits the award of restricted stock, restricted stock units, stock bonus awards and performance-based awards. During 2012, awards to certain employees either cliff vested after one year, or vest annually in 33.3% increments over three years. During 2013, awards to certain employees vested immediately upon the date of grant, or cliff vested after one year provided that the employee remained continuously employed through the issuance date. The Company grants restricted stock awards to non-employee directors of the Company who are unaffiliated with Oaktree Capital Management, LLC (“Oaktree”) and MTS Health Investors, LLC (“MTS”) (“unaffiliated directors”). These awards to unaffiliated directors cliff vest after one year based on the unaffiliated directors’ continued service with the Company through that date. For the six months ended June 30, 2014 and 2015 , the Company recorded share-based payment related to stock awards of $245 and $344 , respectively. There were no shares of restricted stock granted during the six months ended June 30, 2014 . Restricted stock units ("RSUs") totaling 25,000 were granted to the Company's Chief Executive Officer in the third quarter of 2014, which vest based upon achieving certain market performance conditions. Specifically, the Company's closing stock price per common share must equal or exceed a value of $40.00 per share for 10 consecutive days between the dates of January 1, 2015 and April 21, 2017. If these conditions are not achieved before April 21, 2017, these RSUs will expire. In accordance with ASC 718, expense related to restricted stock units that vest based on achieving a market condition should not be recognized until the derived vesting period has been met, and at such time the derived vesting period becomes the requisite service period. Since the market condition has not been met, and is currently not probable of being met based on the current market condition, the Company has not recognized any expense related to these RSUs. The following table summarizes the Company’s restricted stock activity: Shares Weighted-Average Grant-Date Fair Value Unvested at January 1, 2015 32,959 $ 20.99 Granted to employees — — Granted to non-employee directors — — Vested — — Canceled — — Unvested at June 30, 2015 32,959 $ 20.99 At June 30, 2015 , there is no unrecognized fair value share-based payment expense related to restricted stock awards granted to employees. At June 30, 2015 , the total unrecognized fair value share-based payment expense related to the restricted stock awards granted to unaffiliated directors was $345 , which is expected to be recognized over a remaining weighted-average period of 0.50 years. Directors' Compensation Program In 2014 and 2015, under the compensation program for non-employee directors, non-employee directors earn an annual fee of $40 for their services as directors. In addition, each unaffiliated director received a restricted stock unit award on December 31 for the number of shares of our Common Stock having a value equal to $140 , using the average share price of our Common Stock over the 15 -day period preceding the grant date. These restricted stock unit awards vest on the first anniversary of their respective date of grant contingent upon the unaffiliated director's continued service to the Company through that date. In addition to the annual fee for all non-employee directors, each affiliated director receives additional annual cash compensation of $140 , paid in one annual installment, for serving on the Board during 2014 and 2015. Beginning October 1, 2013, during the 24 -month period following his resignation as the Company's CEO, the Chairman of the Board, Mr. Buckelew, is granted restricted stock units having a value equal to $138 as compensation for each service period of one year. Also during 2014, non-employee directors who served as members of our Audit Committee received an additional $15 , and the non-employee director who served as Chairman of our Audit Committee received an additional $30 . In 2014, non-employee directors who served as members of our Nominating Committee and Compensation Committee received an additional $5 . In 2014, non-employee directors were reimbursed for travel expenses related to their Board service.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Recognition In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU number 2014-09, “Revenue from Contracts with Customers (Topic 606)" — to clarify and converge the revenue recognition principles under U.S. GAAP and IFRS and to develop guidance that would streamline and enhance revenue recognition requirements while also providing a more robust framework for addressing revenue issues. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. Key provisions of the ASU involve a 5-step model specific to recognizing revenue derived from customer contracts. In addition, ASU 2014-09 provides implementation guidance on several other important topics, including the accounting for certain revenue-related costs. The adoption of ASU 2014-09 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is not permitted. On April 29, 2015, the FASB proposed a one-year deferral for the effective date of the new standard. The Company is assessing the impact, if any, that the adoption of ASU 2014-09 may have on the Company's results of operations, cash flows, or financial position. Going Concern In August 2014, the FASB issued ASU number 2014-15, "Presentation of Financial Statements—Going Concern (Subtopic 205-40)". Under U.S. GAAP, a going concern is presumed unless and until an entity’s liquidation becomes imminent. When an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, "Presentation of Financial Statements—Liquidation Basis of Accounting." However, there may be conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, even if liquidation is not imminent. In those situations, financial statements should continue to be prepared under the going concern basis of accounting. ASU 2014-15 provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to determine whether to disclose information about relevant conditions and events. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is assessing the impact, if any, that the adoption of ASU 2014-15 may have on the Company's results of operations, cash flows, or financial position.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company used the following methods and assumptions in estimating fair value disclosure for financial instruments: Cash and cash equivalents The carrying amounts reported in the balance sheets approximate fair value due to the short-term maturity or variable rates of these instruments. Debt The carrying amount of fixed and variable-rate borrowings at June 30, 2015 approximates fair value estimated based on current market rates and credit spreads for similar debt instruments. Derivative instruments Fair value was determined based on the income approach and standard valuation techniques to convert future amounts to a single present amount and approximates the net gains and losses that would have been realized if the contracts had been settled at each period-end. The estimated fair values of the Company’s financial instruments are as follows: December 31, 2014 June 30, 2015 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 33,033 $ 33,033 $ 43,399 $ 43,399 Fixed-rate debt 13,015 13,878 24,154 23,774 Variable-rate debt 494,274 494,354 518,994 518,122 Contingent consideration related to acquisition — — 1,800 1,800 Derivative instruments - asset position 228 228 11 11 Derivative instruments - liability position 46 46 41 41 ASC 820, “Fair Value Measurement,” applies to all assets and liabilities that are being measured and reported at fair value on a recurring basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in generally accepted accounting principles by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Quoted market prices in active markets for identical assets or liabilities. Level 2 Observable market based inputs or unobservable inputs, including identical securities in inactive markets or similar securities in active markets, that are corroborated by market data. Level 3 Unobservable inputs that are not corroborated by market data. None of the Company’s instruments have transferred from one level to another. The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of December 31, 2014: Total Quoted market prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Cash and cash equivalents $ 33,033 $ 33,033 $ — $ — Interest rate contracts - asset position 228 228 Interest rate contracts - liability position 46 — 46 — The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of June 30, 2015 : Total Quoted market prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Cash and cash equivalents $ 43,399 $ 43,399 $ — $ — Contingent consideration related to acquisition 1,800 — — 1,800 Interest rate contracts - asset position 11 — 11 — Interest rate contracts - liability position 41 — 41 — The Company’s derivative instruments are primarily pay-fixed, receive-variable interest rate swaps and caps based on the LIBOR swap rate. The Company has elected to use the income approach to value these derivatives, using observable Level 2 market expectations at measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated, but not compelled to transact. Level 2 inputs for interest rate swap and cap valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically futures contracts on LIBOR for the first two years) and inputs other than quoted prices that are observable for the asset or liability (specifically LIBOR cash and swap rates at commonly quoted intervals and implied volatilities for options). ASC 820 states that the fair value measurement of an asset or liability must reflect the nonperformance risk of the entity and the counterparty. Therefore, the impact of the counterparty’s creditworthiness and the Company’s creditworthiness has also been factored into the fair value measurement of the derivative instruments. For additional information please see Note 9 of the Notes to the Condensed Consolidated Financial Statements. The Company purchased TPC in February 2015 and recorded the related goodwill and intangible assets at their fair value which was estimated using the income approach and unobservable level 3 inputs. The fair value of noncontrolling interest related to the transaction was estimated using the implied fair value based on the Company's ownership percentage. For additional information please see Note 2 of the Notes to the Condensed Consolidated Financial Statements. During the quarter ended June 30, 2015, the Company recorded a non-cash charge to write off $6.7 million of intangible assets not subject to amortization in its Radiation Oncology division. For additional information please see Note 6 of the Notes to the Condensed Consolidated Financial Statements.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Changes in the carrying amount of goodwill are as follows: Balance at January 1, 2014 $ 56,975 Goodwill acquired during the period 6,889 Impairment charges — Adjustments to goodwill during the period — Balance at December 31, 2014 63,864 Goodwill acquired during the period 22,611 Impairment charges — Adjustments to goodwill during the period — Balance at June 30, 2015 $ 86,475 Gross goodwill $ 260,719 Accumulated impairment charges (174,244 ) Balance at June 30, 2015 $ 86,475 Intangible assets consisted of the following: December 31, 2014 June 30, 2015 Gross Carrying Amount Accumulated Amortization Intangible Assets, net Gross Carrying Amount Accumulated Amortization Intangible Assets, net Amortizing intangible assets: Customer contracts $ 162,089 $ (93,617 ) $ 68,472 $ 175,864 $ (97,485 ) $ 78,379 Other 26,241 (21,758 ) 4,483 37,341 (22,414 ) 14,927 Total amortizing intangible assets $ 188,330 $ (115,375 ) $ 72,955 $ 213,205 $ (119,899 ) $ 93,306 Intangible assets not subject to amortization 42,975 36,305 Total other intangible assets $ 115,930 $ 129,611 In 2015, the Company intends to perform an annual impairment test in the fourth quarter for goodwill and indefinite life intangible assets based on the financial information as of September 30, absent of other events occurring or changes in circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company compares the fair value of its reporting units to its carrying amount to determine if there is potential impairment. The fair value of the reporting unit is determined by an income approach and a market capitalization approach. Significant management judgment is required in the forecasts of future operating results that are used in the income approach. The estimates that the Company has used are consistent with the plans and estimates that it uses to manage its business. The Company bases its fair value estimates on forecasted revenue and operating costs which include a number of factors including, but not limited to, securing new customers, retention of existing customers, growth in imaging and radiation oncology revenues and the impact of continued cost savings initiatives. However, it is possible that plans and estimates may change. During the quarter ended June 30, 2015, the Company implemented a plan to start the process to close a radiation therapy center and, as a result, recorded a non-cash charge to write off $6.7 million of intangible assets not subject to amortization associated with that center in its Radiation Oncology division. The Company concluded that no other events occurred or circumstances changed relating to any other of its intangible assets during the quarter ended June 30, 2015 and will perform its annual impairment test for goodwill and other intangibles assets during the fourth quarter of 2015 , as described above. The Company uses the estimated useful life to amortize customer contracts, which is a weighted-average of 15 years. Other intangible assets subject to amortization are estimated to have a weighted-average useful life of six years. Amortization expense for intangible assets subject to amortization was $1,957 and $2,495 for the quarters ended June 30, 2014 and 2015 , respectively, and $3,909 and $4,530 for the six months ended June 30, 2014 and 2015 , respectively. The intangible assets not subject to amortization represent certificates of need and regulatory authority rights which have indefinite useful lives. Estimated annual amortization expense for each of the fiscal years ending December 31, is presented below: 2015 $ 8,875 2016 7,930 2017 7,491 2018 7,131 2019 6,647 Thereafter 59,756

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2015
Other Accrued Liabilities [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consisted of the following: December 31, 2014 June 30, 2015 Accrued systems rental and maintenance costs $ 1,586 $ 2,457 Accrued site rental fees 992 940 Accrued property and sales taxes payable 9,276 9,973 Accrued self-insurance expense 2,276 2,657 Deferred gain on sale of equipment 312 312 Other accrued expenses 12,100 14,132 Total $ 26,542 $ 30,471

Long-Term Debt and Senior Subor

Long-Term Debt and Senior Subordinated Credit Facility	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Long-Term Debt and Senior Subordinated Credit Facility	Long-Term Debt and Senior Subordinated Credit Facility Long-term debt consisted of the following: December 31, 2014 June 30, 2015 Term loan facility $ 482,825 $ 505,474 Discount on term loan facility (2,156 ) (2,074 ) Revolving credit facility 2,000 — Equipment debt 24,620 39,748 Long-term debt, including current portion 507,289 543,148 Less current portion 15,512 22,484 Long-term debt $ 491,777 $ 520,664 Senior Secured Term Loan Refinancing On June 3, 2013, the Company replaced its existing credit facility with a new senior secured credit agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Credit Agreement”). The Credit Agreement consists of (i) a $340,000 , six -year term loan facility, (ii) a $50,000 , five -year revolving loan facility, including a $20,000 sublimit for letters of credit, (iii) uncommitted incremental loan facilities of $100,000 of revolving or term loans, plus an additional amount if the Company's pro forma leverage ratio is less than or equal to 3.25 , subject to receipt of lender commitments and satisfaction of specified conditions, and (iv) an $80,000 delayed draw term loan facility, which was required to be drawn within thirty days of June 3, 2013 and used for the redemption of $190,000 in aggregate principal amount of the Company's 8% Senior Notes. On July 3, 2013 the delayed draw term loan facility was utilized, of which the proceeds were used to redeem $80,000 in aggregate principal amount of the Company's outstanding 8% Senior Notes that were originally issued in December 2009 as a cash tender offer for any and all of its outstanding 7.25% Notes originally issued in December of 2004. The delayed draw term loan facility converted into, and matched the terms of, the new $340,000 term loan facility. Borrowings under the Credit Agreement bear interest through maturity at a variable rate based upon, at the Company's option, either the London interbank offered rate ("LIBOR") or the base rate (which is the highest of the administrative agent’s prime rate, one-half of 1.00% in excess of the overnight federal funds rate, and 1.00% in excess of the one-month LIBOR rate), plus, in each case, an applicable margin. With respect to the term loan facilities, the applicable margin for LIBOR loans is 3.25% per annum, and with respect to the revolving loan facilities, the applicable margin for LIBOR loans ranges, based on the applicable leverage ratio, from 3.00% to 3.25% per annum, in each case, with a LIBOR floor of 1.00% . The applicable margin for base rate loans under the term loan facilities is 2.25% per annum and under the revolving loan facility ranges, based on the applicable leverage ratio, from 2.00% to 2.25% per annum. Prior to the refinancing of the term loan facilities, the applicable margin for base rate loans was 4.25% per annum and the applicable margin for revolving loans was 5.25% per annum, with a LIBOR floor of 2.00% . The Company is required to pay a commitment fee which ranges, based on the applicable leverage ratio, from 0.375% to 0.50% per annum on the undrawn portion available under the revolving loan facility and variable per annum fees with respect to outstanding letters of credit. During the first five and three-quarter years after the closing date, and including the full amount of the delayed draw term loan facility, the Company was required to make quarterly amortization payments of the term loans in the amount of $1,050 . The Company is also required to make mandatory prepayments of term loans under the Credit Agreement, subject to specified exceptions, from excess cash flow (as defined in the Credit Agreement), and with the proceeds of asset sales, debt issuances and specified other events. Obligations under the Credit Agreement are guaranteed by substantially all the Company's direct and indirect domestic subsidiaries. The obligations under the Credit Agreement and the guarantees are secured by a lien on substantially all tangible and intangible property, and by a pledge of all of the shares of stock and limited liability company interests of the Company's direct and indirect domestic subsidiaries, of which the Company now owns or later acquires more than a 50% interest, subject to limited exceptions. In addition to other covenants, the Credit Agreement places limits on the ability of the Company and its subsidiaries to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, transact with affiliates and alter the business conducted by the Company and its subsidiaries. The Credit Agreement also contains a leverage ratio covenant requiring the Company to maintain a maximum ratio of consolidated total debt to consolidated adjusted EBITDA that ranges from 4.95 to 1.00 to 4.30 to 1.00. For the quarter ended June 30, 2015 , the Credit Agreement required a maximum leverage ratio of not more than 4.85 to 1.00. The Credit Agreement eliminated the interest coverage ratio covenant which the Company was subject to maintain prior to the refinancing. Failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare all amounts borrowed under the Credit Agreement, together with accrued interest and fees, to be immediately due and payable, and to terminate all commitments under the Credit Agreement. On October 11, 2013, the Company entered into an amendment to the Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “First Amendment”). Pursuant to the First Amendment, the Company raised $70,000 in incremental term loan commitments to repurchase the remaining Notes. On December 2, 2013, the Company borrowed $70,000 of incremental term loans, and with such proceeds plus borrowings under its revolving line of credit and cash on hand, completed the redemption of all of its outstanding Notes on December 4, 2013. On June 19, 2015, the Company entered into a second amendment to the Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Second Amendment”). Pursuant to the Second Amendment, the Company raised the remaining $30,000 in incremental term loan commitments. The funds were used to repay all outstanding borrowings under the Company's revolving credit facility, pay fees and expenses related to the Second Amendment, and general corporate purposes. The Second Amendment did not impact the borrowing capacity on the revolving credit facility which remained at $50,000 . The initial portion of the incremental term loan was funded at 99.0% of principal amount under the First Amendment and the remainder was funded at 99.5% of principal under the Second Amendment. The incremental term loan has all of the same terms as the existing term loan facilities and will mature in June 2019. Interest on the incremental term loan is calculated, at the Company's option, at a base rate plus a 2.25% margin or LIBOR plus a 3.25% margin, subject to a 1.00% LIBOR floor. As of June 30, 2015 , there was $505,474 outstanding under the term loan facility, which included the draw term facility and the incremental term facility, and $0 borrowings were outstanding under the revolving credit facility. As of June 30, 2015 , the Company’s ratio of consolidated total debt to consolidated adjusted EBITDA calculated pursuant to the Credit Agreement was 3.98 to 1.00 . The quarterly amortization payments of all term loans under the credit facility for the first five and three-quarter years was initially established at $1,050 . The quarterly amortization payment was increased to $1,225 in December 2013 pursuant to the First Amendment and subsequently increased to $1,300 in June 2015 pursuant to the Second Amendment. During the six months ended June 30, 2015 , the increase in the Company's current portion of long-term debt was primarily due to borrowings for equipment expenditures for its Radiation Oncology division's joint venture with the Medical University of South Carolina ("MUSC"). Debt related to MUSC was funded through a line of credit exclusive of the Company's revolving line of credit, and will be converted to term notes as phases of the project are completed.

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2015
Summary of Derivative Instruments [Abstract]
Derivatives	Derivatives The Company accounts for derivative instruments and hedging activities in accordance with the provisions of ASC 815, “Derivatives and Hedging.” Management generally designates derivatives in a hedge relationship with the identified exposure on the date the Company enters into a derivative contract, as disclosed below. The Company has only executed derivative instruments that are economic hedges of exposures that can qualify in hedge relationships under ASC 815. The Company formally documents all relationships between hedging instruments and hedged items, as well as the risk-management objective and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the firm commitment or forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally assesses effectiveness of its hedging relationships, both at the hedge inception and on an ongoing basis, then measures and records ineffectiveness. The Company would discontinue hedge accounting prospectively (i) if it is determined that the derivative is no longer effective in offsetting change in the cash flows of a hedged item, (ii) when the derivative expires or is sold, terminated or exercised, (iii) because it is probable that the forecasted transaction will not occur, or (iv) if management determines that designation of the derivative as a hedge instrument is no longer appropriate. The Company’s derivatives are recorded on the balance sheet at their fair value. For additional information please see Note 5 of the Notes to the Condensed Consolidated Financial Statements. For derivatives accounted for as cash flow hedges, any effective unrealized gains or losses on fair value are included in comprehensive income (loss), net of tax, and any ineffective gains or losses are recognized in income immediately. Amounts recorded in comprehensive income are reclassified to earnings when the hedged item impacts earnings. Cash Flow Hedges Interest Rate Cash Flow Hedges The Company has entered into multiple interest rate swap and cap agreements to hedge the future cash interest payments on portions of its variable rate bank debt. For the six months ended June 30, 2014 and 2015 , the Company had interest rate swap and cap agreements to hedge approximately $258,500 and $257,075 of its variable rate bank debt, respectively, or 50.9% and 47.3% of total debt, respectively. Over the next twelve months, the Company expects to reclassify $351 from accumulated comprehensive loss to interest expense and other, net. In the first quarter of 2010, the Company entered into three interest rate cap agreements, in accordance with Company policy, to avoid unplanned volatility in the income statement due to changes in the LIBOR interest rate environment. The interest rate cap agreements matured in February 2014 , had a total notional amount of $150,000 , and were de-designated as cash flow hedges associated with the Company’s variable rate bank debt in the fourth quarter of 2013. In the second quarter of 2011, the Company acquired two interest rate swap agreements (the “USR Swaps”) as part of the acquisition of US Radiosurgery, LLC ("USR"). One of the USR Swaps, which matures in October 2015 , had a notional amount of $349 as of June 30, 2015 . Under the terms of this agreement, the Company receives one-month LIBOR and pays a fixed rate of 5.71% . The net effect of the hedge is to record interest expense at a fixed rate of 8.71% , as the underlying debt incurred interest based on one-month LIBOR plus 3.00% . The other USR Swap matured in April 2014 . As a result of the acquisition of USR, the USR Swap was de-designated, hedge accounting was terminated and all further changes in the fair market value of the swap is being recorded in interest expense and other, net. In the fourth quarter of 2012, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in December 2017, had a notional amount of $2,717 as of June 30, 2015 . Under the terms of this agreement, the Company receives one-month LIBOR plus 2.50% and pays a fixed rate of 3.75% . The net effect of the hedge is to convert interest expense to a fixed rate of 3.75% , as the underlying debt incurred interest based on one-month LIBOR plus 2.50% . In the first quarter of 2013, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in April 2018, had a notional amount of $2,491 as of June 30, 2015 . Under the terms of this agreement, the Company receives one-month LIBOR plus 2.00% and pays a fixed rate of 2.873% . The net effect of the hedge is to convert interest expense to a fixed rate of 2.873% , as the underlying debt incurred interest based on one-month LIBOR plus 2.00% . In the fourth quarter of 2013, the Company entered into five interest rate cap agreements ("2013 Caps"), in accordance with Company policy, to avoid unplanned volatility in the income statement due to changes in the LIBOR interest rate environment. The 2013 Caps, which mature in December 2016, had a notional amount of $250,000 and were designated as cash flow hedges of future cash interest payments associated with a portion of the Company’s variable rate bank debt. Under these arrangements, the Company has purchased a cap on LIBOR at 2.50% . The Company paid $815 to enter into the caps, which is being amortized through interest expense and other, net over the life of the agreements. In the fourth quarter of 2014, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in November 2019, had a notional amount of $1,519 as of June 30, 2015. Under the terms of this agreement, the Company receives one-month LIBOR and pays a fixed rate of 1.34% . The net effect of the hedge is to convert interest expense to a fixed rate of 1.34% , as the underlying debt incurred interest based on one-month LIBOR. The Effect of Designated Derivative Instruments on the Statement of Operations For the Quarter Ended June 30, 2014 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (375 ) Interest expense and other, net $ 8 Interest expense and other, net $ — The Effect of Designated Derivative Instruments on the Statement of Operations For the Six Months Ended June 30, 2014 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (478 ) Interest expense and other, net $ (126 ) Interest expense and other, net $ (2 ) The Effect of Designated Derivative Instruments on the Statement of Operations For the Quarter Ended June 30, 2015 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (19 ) Interest expense and other, net $ 5 Interest expense and other, net $ — The Effect of Designated Derivative Instruments on the Statement of Operations For the Six Months Ended June 30, 2015 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (208 ) Interest expense and other, net $ 16 Interest expense and other, net $ 1 The Effect of Non-Designated Derivative Instruments on the Statements of Operations for the quarter and six months ended June 30, 2014 and 2015 was immaterial.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the quarter and six months ended June 30, 2014 , the Company recorded income tax expense of $1,802 and $3,309 , or 39.3% and 41.2% , of the Company’s pretax income. For the quarter and six months ended June 30, 2015 , the Company recorded income tax (benefit) expense of $(1,366) and $206 , or 41.0% and (5,725.0)% , of the Company’s pretax income. The Company’s effective tax rate for the quarter and six months ended June 30, 2015 differed from the federal statutory rate principally as a result of discrete tax benefit shortfalls of $204 from share based payments, which also resulted in an income tax expense of $206 relative to a net loss of $210 and a corresponding minimal amount of pretax loss for the six month period. As of June 30, 2015 , the Company has provided a liability for $301 of unrecognized tax benefits related to various federal and state income tax matters. The tax-effected amount that would reduce the Company’s effective income tax rate if recognized is $256 . The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. As of June 30, 2015 , the Company had approximately $16 in accrued interest and penalties related to unrecognized tax benefits. The Company is subject to United States federal income tax as well as income tax of multiple state tax jurisdictions. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2011 through 2014. The Company’s and its subsidiaries’ state income tax returns are open to audit under the applicable statutes of limitations for the years ended December 31, 2010 through 2014. The Company does not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months .

Earnings Per Common Share

Earnings Per Common Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings Per Common Share Basic net income per share is computed utilizing the two-class method and is calculated based on the weighted-average number of common shares outstanding during the periods presented, excluding nonvested restricted stock units which do not contain nonforfeitable rights to dividend and dividend equivalents. Diluted net income per share is computed using the weighted-average number of common and common equivalent shares outstanding during the periods utilizing the two-class method for stock options, nonvested restricted stock and nonvested restricted stock units. Potentially dilutive securities are not considered in the calculation of net loss per share as their impact would be anti-dilutive. The following table sets forth the computation of basic and diluted earnings per share: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Numerator: Net income (loss) attributable to Alliance HealthCare Services, Inc. $ 2,784 $ (1,961 ) $ 4,715 $ (210 ) Denominator: Weighted-average shares-basic 10,671 10,715 10,669 10,714 Effect of dilutive securities: Employee stock options 183 121 203 125 Weighted-average shares-diluted 10,854 10,836 10,872 10,839 Income (loss) per common share attributable to Alliance HealthCare Services, Inc.: Basic $ 0.26 $ (0.18 ) $ 0.44 $ (0.02 ) Diluted $ 0.26 $ (0.18 ) $ 0.43 $ (0.02 ) Stock options excluded from the computation of diluted per share amounts: Weighted-average shares for which the exercise price exceeds average market price of common stock 132 394 134 335 Average exercise price per share that exceeds average market price of common stock $ 44.22 $ 30.15 $ 44.25 $ 31.57

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies In the normal course of business, the Company has made certain guarantees and indemnities, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain transactions. The Company indemnifies other parties, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed to hold the other party harmless against losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims arising from a breach of representations or covenants. In addition, the Company has entered into indemnification agreements with its executive officers and directors and the Company's bylaws contain similar indemnification obligations. Under these arrangements, the Company is obligated to indemnify, to the fullest extent permitted under applicable law, its current or former officers and directors for various amounts incurred with respect to actions, suits or proceedings in which they were made, or threatened to be made, a party as a result of acting as an officer or director. It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. Historically, payments made related to these indemnifications have been immaterial. At June 30, 2015 , the Company has determined that no liability is necessary related to these guarantees and indemnities. On June 14, 2013, Alliance Oncology, LLC, a subsidiary of the Company, filed a complaint against Harvard Vanguard Medical Associates, Inc. (“HVMA”) in the United States District Court for the District of Massachusetts, including several claims seeking damages resulting from HVMA’s early termination of a long-term services agreement between the two companies. HVMA filed an answer to Alliance Oncology’s complaint on August 27, 2013. Without specifying its alleged damages, HVMA also asserted several counterclaims in its answer. The Company filed its answer to HVMA’s counterclaims on October 4, 2013, and intends to vigorously defend against the claims asserted. The Company has not recorded an expense related to any potential damages in connection with this matter because any potential loss is not probable or reasonably estimable at this time. On February 10, 2015, Alliance Oncology was served with a lawsuit in the United States District Court for the Western District of Missouri by Dr. Barry Michael Driver. The Plaintiff is an employed Physician at Alliance Oncology’s Joplin, Missouri, Radiation Therapy Cancer Treatment Center. The Plaintiff alleges Alliance Oncology breached his employment agreement by failing to pay him in accordance with the terms of the contract. Alliance Oncology disputes Dr. Driver’s interpretation of the employment agreement and asserts Dr. Driver was paid appropriately. On or about July 14, 2015, the District Court granted Alliance Oncology’s Motion to Dismiss and dismissed three of the four Counts contained within Plaintiff’s Complaint. Alliance Oncology is currently in the process of preparing its Answer to the remaining Count, and also engaged in settlement discussions with Dr. Driver, who remains a current employee at this time. The Company from time to time is involved in routine litigation and regulatory matters incidental to the conduct of its business. The Company believes that resolution of such matters will not have a material adverse effect on its consolidated results of operations, financial position, or cash flows.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions On April 16, 2007, Oaktree and MTS purchased 4,900,301 shares of the Company’s common stock. Upon completion of the transaction, Oaktree and MTS owned in the aggregate approximately 49.7% of the outstanding shares of common stock of the Company. At June 30, 2015 , Oaktree and MTS owned in the aggregate approximately 50.7% of the outstanding shares of common stock of the Company. The Company does not pay management fees to Oaktree and MTS for their financial advisory services to the Company. Revenues from management agreements with unconsolidated equity investees were $2,241 and $2,209 during the quarters ended June 30, 2014 and 2015 , respectively. Revenues from management agreements with unconsolidated equity investees were $4,562 and $4,587 during the six months ended June 30, 2014 and 2015 , respectively. The Company provides services as part of its ongoing operations for and on behalf of the unconsolidated equity investees, which are included in the management agreement revenue, who reimburse the Company for the actual amount of the expenses incurred. The Company records the expenses as cost of revenues and the reimbursement as revenues in its condensed consolidated statements of operations and comprehensive income (loss). For the quarters ended June 30, 2014 and 2015 , the amounts of the revenues and expenses were $1,783 and $1,782 , respectively. For the six months ended June 30, 2014 and 2015 , the amounts of the revenues and expenses were $3,687 and $3,729 , respectively. On June 3, 2013, the Company replaced its existing credit facility with a new senior secured credit agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Credit Agreement”). Of the other lenders, Oaktree funded approximately $40,476 of the $340,000 six -year term loan facility. In addition, as of July 3, 2013, Oaktree funded approximately $9,524 of the $80,000 delayed draw. On December 2, 2013, the Company borrowed $70,000 of the incremental term loans from its current lenders under its Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent. The Company used the proceeds from the transaction plus borrowings under its revolving line of credit and cash on hand to complete the redemption of all its outstanding Notes on December 4, 2013. Oaktree funded $10,000 of the $70,000 incremental term loan.

Investments in Unconsolidated I

Investments in Unconsolidated Investees	6 Months Ended
	Jun. 30, 2015
Investments in Unconsolidated Investees [Abstract]
Investments in Unconsolidated Investees	Investments in Unconsolidated Investees The Company has direct ownership in three unconsolidated investees at June 30, 2015 . The Company owns between 15% and 50% of these investees, and provides management services under agreements with these investees, expiring at various dates through 2025. All of these investees are accounted for under the equity method since the Company does not exercise control over the operations of these investees. During 2014, in accordance with ASC 323, “Investments—Equity Method and Joint Ventures,” the Company wrote off its remaining investment in one of its unconsolidated investees that was originally acquired in 2011. The impairment charge totaled $236 and is related to the closure of one cancer center in the second quarter of 2014 due to the expiration of one of its non-compete agreements with the affiliated oncology physician. Impairment charges related to this event were taken in 2013 for a physicians' referral network, trademarks, and professional services agreement, which were all written down to zero value. Set forth below are certain financial data for Alliance-HNI, LLC and Subsidiaries, one of the Company’s unconsolidated investees as of: December 31, 2014 June 30, 2015 Balance Sheet Data: Current assets $ 4,721 $ 4,319 Noncurrent assets 9,257 8,605 Current liabilities 2,773 2,513 Noncurrent liabilities 3,272 2,657 Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Operating Results: Revenues $ 4,225 $ 4,237 $ 8,331 $ 8,401 Expenses 2,266 2,201 4,821 4,605 Net income 1,959 2,036 3,510 3,796 Earnings from unconsolidated investee 979 1,018 1,755 1,898 Set forth below are certain financial data for the aggregate of the Company’s unconsolidated investees, including Alliance-HNI, LLC and Subsidiaries as of: December 31, 2014 June 30, 2015 Balance Sheet Data: Current assets $ 8,687 $ 6,992 Noncurrent assets 10,108 9,182 Current liabilities 3,760 3,477 Noncurrent liabilities 3,395 2,693 Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Combined Operating Results: Revenues $ 6,765 $ 6,469 $ 13,196 $ 13,106 Expenses 3,210 2,920 6,745 6,256 Net income 3,555 3,549 6,451 6,850 Earnings from unconsolidated investees 1,242 1,292 2,240 2,455

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	Stockholders’ Deficit The following table summarizes consolidated stockholders’ deficit, including noncontrolling interest. Additional Accumulated Stockholders’ Equity (Deficit) Attributable to Total Common Stock Treasury Stock Paid-In Comprehensive Accumulated Alliance HealthCare Noncontrolling Stockholders’ Shares Amount Shares Amount Capital Income (Loss) Deficit Services, Inc. Interest Deficit Balance at January 1, 2015 10,713,658 $ 107 (157,973 ) $ (3,138 ) $ 27,653 $ (351 ) $ (194,091 ) $ (169,820 ) $ 58,340 $ (111,480 ) Exercise of stock options 2,515 — — — 25 — — 25 — 25 Purchase of treasury stock — — — — — — — — — — Share-based payment — — — — 819 — — 819 — 819 Share-based payment income tax benefit — — — — (82 ) — — (82 ) — (82 ) Unrealized loss on hedging transaction, net of tax — — — — — (141 ) — (141 ) — (141 ) Net investments in subsidiaries — — — — — — — — 12,246 12,246 Net income (loss) — — — — — — (210 ) (210 ) 9,250 9,040 Balance at June 30, 2015 10,716,173 $ 107 (157,973 ) $ (3,138 ) $ 28,415 $ (492 ) $ (194,301 ) $ (169,409 ) $ 79,836 $ (89,573 )

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. In accordance with ASC 280, “Segment Reporting,” and based on the nature of the financial information that is received by the CODM, the Company operates in three operating segments, of which two are reportable segments, Radiology and Radiation Oncology, based on similar economic and other characteristics. The Radiology segment is comprised of diagnostic imaging services including MRI, PET/CT and other imaging services. The Radiation Oncology segment is comprised of radiation oncology services. All intercompany revenues, expenses, payables and receivables are eliminated in consolidation and are not reviewed when evaluating segment performance. Each segment’s performance is evaluated based on Revenue, Segment Income and Net Income. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 1 of the Notes to the Consolidated Financial Statements on Form 10-K for the year ended December 31, 2014. Additionally, the Company does not consider its wholesale revenue and retail revenue sources to constitute separate operating segments as discrete financial information does not exist and is not provided to the CODM. The following table summarizes the Company’s revenue by segment: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Revenue Radiology $ 87,297 $ 84,994 $ 171,935 $ 166,381 Radiation Oncology 23,941 25,330 44,668 49,516 Corporate / Other — 8,180 — 12,036 Total $ 111,238 $ 118,504 $ 216,603 $ 227,933 The following are components of revenue: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Revenue MRI $ 45,637 $ 45,249 $ 89,822 $ 88,136 PET/CT 34,178 32,594 67,547 64,144 Radiation Oncology 23,941 25,330 44,668 49,516 Other radiology 7,482 7,151 14,566 14,101 Corporate / Other — 8,180 — 12,036 Total $ 111,238 $ 118,504 $ 216,603 $ 227,933 Segment income represents net income before income taxes; interest expense and other, net; amortization expense; depreciation expense; share-based payment; severance and related costs; noncontrolling interest in subsidiaries; restructuring charges; transaction costs; impairment charges, loss on extinguishment of debt, other nonrecurring charges, and non-cash charges. Segment income is the most frequently used measure of each segment’s performance by the CODM and is commonly used in setting performance goals. The following table summarizes the Company’s segment income (loss): Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Segment income (loss) Radiology $ 33,248 $ 28,419 $ 64,257 $ 54,793 Radiation Oncology 11,167 12,581 20,490 24,344 Corporate / Other (7,746 ) (6,985 ) (15,126 ) (15,006 ) Total $ 36,669 $ 34,015 $ 69,621 $ 64,131 The reconciliation of net income (loss) to total segment income is shown below: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Net income (loss) attributable to Alliance HealthCare Services, Inc. $ 2,784 $ (1,961 ) $ 4,715 $ (210 ) Income tax expense (benefit) 1,802 (1,366 ) 3,309 206 Interest expense and other, net 6,124 6,904 12,362 12,922 Amortization expense 1,957 2,495 3,909 4,530 Depreciation expense 14,274 12,072 30,069 23,705 Share-based payment (included in selling, general and administrative expenses) 376 430 710 819 Severance and related costs 1,727 195 1,860 454 Noncontrolling interest in subsidiaries 4,036 4,903 7,085 9,250 Restructuring charges (Note 2) 1,563 236 2,455 491 Transaction costs 937 1,113 939 1,532 Impairment charges 236 6,670 236 6,746 Legal settlements 822 1,543 1,621 2,903 Other non-cash charges (included in other income and expense, net) 31 781 351 783 Total segment income $ 36,669 $ 34,015 $ 69,621 $ 64,131 Net income (loss) for the Radiology and Radiation Oncology segments does not include charges for interest expense, net of interest income, income taxes or certain selling, general and administrative expenses. These costs are charged against the Corporate / Other segment. The following table summarizes the Company’s net income (loss) by segment: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Net income (loss) Radiology $ 20,623 $ 17,937 $ 37,817 $ 34,934 Radiation Oncology 4,642 (1,629 ) 8,068 3,395 Corporate / Other (22,481 ) (18,269 ) (41,170 ) (38,539 ) Total $ 2,784 $ (1,961 ) $ 4,715 $ (210 ) The following table summarizes the Company’s identifiable assets by segment: As of December 31, 2014 As of June 30, 2015 Identifiable assets Radiology $ 229,141 $ 238,810 Radiation Oncology 182,880 180,990 Corporate / Other 88,864 146,616 Total $ 500,885 $ 566,416 The following table summarizes the Company’s goodwill by segment: Radiology Radiation Oncology Corporate / Other Total Balance at January 1, 2014 $ 42,166 $ 14,809 $ — $ 56,975 Goodwill acquired during the period — 6,889 — 6,889 Impairment charges — — — — Adjustments to goodwill during the period — — — — Balance at December 31, 2014 $ 42,166 $ 21,698 $ — $ 63,864 Goodwill acquired during the period — — 22,611 22,611 Impairment charges — — — — Adjustments to goodwill during the period — — — — Balance at June 30, 2015 $ 42,166 $ 21,698 $ 22,611 $ 86,475 Gross goodwill $ 196,508 $ 41,600 $ 22,611 $ 260,719 Accumulated impairment charges (154,342 ) (19,902 ) — (174,244 ) Balance at June 30, 2015 $ 42,166 $ 21,698 $ 22,611 $ 86,475 The following table summarizes the cash used for capital expenditures for the Radiology, Radiation Oncology and Corporate segments: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Cash used for capital expenditures Radiology $ 4,761 $ 5,865 $ 6,828 $ 12,695 Radiation Oncology 19 3,022 19 3,757 Corporate / Other 2,741 2,806 6,409 2,806

Basis of Presentation, Princi22

Basis of Presentation, Principles of Consolidation, and Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the quarter and six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 . The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2014 .
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company records noncontrolling interest related to its consolidated subsidiaries which are not wholly owned. Investments in non-consolidated investees are accounted for under the equity method.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Share-based Payment	The Company has adopted ASC 718, “Compensation—Stock Compensation,” and has elected to follow the alternative transition method as described in ASC 718 for computing its beginning additional paid-in capital pool. In addition, the Company treats the tax deductions from stock options as being realized when they reduce taxes payable in accordance with the principles and timing under the relevant tax law.
Derivatives	The Company accounts for derivative instruments and hedging activities in accordance with the provisions of ASC 815, “Derivatives and Hedging.” Management generally designates derivatives in a hedge relationship with the identified exposure on the date the Company enters into a derivative contract, as disclosed below. The Company has only executed derivative instruments that are economic hedges of exposures that can qualify in hedge relationships under ASC 815. The Company formally documents all relationships between hedging instruments and hedged items, as well as the risk-management objective and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the firm commitment or forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally assesses effectiveness of its hedging relationships, both at the hedge inception and on an ongoing basis, then measures and records ineffectiveness. The Company would discontinue hedge accounting prospectively (i) if it is determined that the derivative is no longer effective in offsetting change in the cash flows of a hedged item, (ii) when the derivative expires or is sold, terminated or exercised, (iii) because it is probable that the forecasted transaction will not occur, or (iv) if management determines that designation of the derivative as a hedge instrument is no longer appropriate. The Company’s derivatives are recorded on the balance sheet at their fair value. For additional information please see Note 5 of the Notes to the Condensed Consolidated Financial Statements. For derivatives accounted for as cash flow hedges, any effective unrealized gains or losses on fair value are included in comprehensive income (loss), net of tax, and any ineffective gains or losses are recognized in income immediately. Amounts recorded in comprehensive income are reclassified to earnings when the hedged item impacts earnings.
Recent Accounting Pronouncements	Revenue Recognition In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU number 2014-09, “Revenue from Contracts with Customers (Topic 606)" — to clarify and converge the revenue recognition principles under U.S. GAAP and IFRS and to develop guidance that would streamline and enhance revenue recognition requirements while also providing a more robust framework for addressing revenue issues. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. Key provisions of the ASU involve a 5-step model specific to recognizing revenue derived from customer contracts. In addition, ASU 2014-09 provides implementation guidance on several other important topics, including the accounting for certain revenue-related costs. The adoption of ASU 2014-09 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is not permitted. On April 29, 2015, the FASB proposed a one-year deferral for the effective date of the new standard. The Company is assessing the impact, if any, that the adoption of ASU 2014-09 may have on the Company's results of operations, cash flows, or financial position. Going Concern In August 2014, the FASB issued ASU number 2014-15, "Presentation of Financial Statements—Going Concern (Subtopic 205-40)". Under U.S. GAAP, a going concern is presumed unless and until an entity’s liquidation becomes imminent. When an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, "Presentation of Financial Statements—Liquidation Basis of Accounting." However, there may be conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, even if liquidation is not imminent. In those situations, financial statements should continue to be prepared under the going concern basis of accounting. ASU 2014-15 provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to determine whether to disclose information about relevant conditions and events. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is assessing the impact, if any, that the adoption of ASU 2014-15 may have on the Company's results of operations, cash flows, or financial position.

Transactions (Tables)

Transactions (Tables)	6 Months Ended
	Jun. 30, 2015
Business Combinations, Restructuring and Related Activities [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes recognized amounts of identifiable assets acquired and liabilities assumed at the acquisition date: Cash received $ 691 Accounts receivable, net 4,440 Equipment, net 3,346 Other assets 416 Goodwill 22,611 Identifiable intangible assets 24,600 Debt (2,781 ) Other liabilities (3,532 ) Noncontrolling interest (20,598 ) Total consideration $ 29,193

Share-Based Payment (Tables)

Share-Based Payment (Tables)	6 Months Ended
	Jun. 30, 2015
Share-based Compensation [Abstract]
Weighted average assumptions for stock option awards	The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards: Six months ended June 30, 2014 2015 Risk free interest rate 1.83 % 1.65 % Expected dividend yield — % — % Expected stock price volatility 66.3 % 65.2 % Average expected life (in years) 6.00 6.00
Summary of stock option activity	The following table summarizes the Company’s stock option activity: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2015 633,898 $ 21.39 Granted 83,514 23.91 Exercised (2,515 ) 10.12 Canceled (28,117 ) 55.81 Outstanding at June 30, 2015 686,780 $ 20.35 6.02 $ 3,482 Vested and expected to vest in the future at June 30, 2015 662,238 $ 20.18 5.94 $ 3,476 Exercisable at June 30, 2015 488,809 $ 18.14 5.17 $ 3,393
Summary of unvested stock option activity	The following table summarizes the Company’s unvested stock option activity: Shares Weighted-Average Grant-Date Fair Value Unvested at January 1, 2015 197,899 $ 12.13 Granted 83,514 14.25 Vested (78,825 ) 6.08 Canceled (4,617 ) 15.35 Unvested at June 30, 2015 197,971 $ 15.40
Summary of unvested restricted stock activity	The following table summarizes the Company’s restricted stock activity: Shares Weighted-Average Grant-Date Fair Value Unvested at January 1, 2015 32,959 $ 20.99 Granted to employees — — Granted to non-employee directors — — Vested — — Canceled — — Unvested at June 30, 2015 32,959 $ 20.99

Fair Value of Financial Instr25

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Estimated fair values of financial instruments	The estimated fair values of the Company’s financial instruments are as follows: December 31, 2014 June 30, 2015 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 33,033 $ 33,033 $ 43,399 $ 43,399 Fixed-rate debt 13,015 13,878 24,154 23,774 Variable-rate debt 494,274 494,354 518,994 518,122 Contingent consideration related to acquisition — — 1,800 1,800 Derivative instruments - asset position 228 228 11 11 Derivative instruments - liability position 46 46 41 41
Financial instruments reported at fair value on a recurring basis	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of December 31, 2014: Total Quoted market prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Cash and cash equivalents $ 33,033 $ 33,033 $ — $ — Interest rate contracts - asset position 228 228 Interest rate contracts - liability position 46 — 46 — The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of June 30, 2015 : Total Quoted market prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Cash and cash equivalents $ 43,399 $ 43,399 $ — $ — Contingent consideration related to acquisition 1,800 — — 1,800 Interest rate contracts - asset position 11 — 11 — Interest rate contracts - liability position 41 — 41 —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the carrying amount of goodwill	Changes in the carrying amount of goodwill are as follows: Balance at January 1, 2014 $ 56,975 Goodwill acquired during the period 6,889 Impairment charges — Adjustments to goodwill during the period — Balance at December 31, 2014 63,864 Goodwill acquired during the period 22,611 Impairment charges — Adjustments to goodwill during the period — Balance at June 30, 2015 $ 86,475 Gross goodwill $ 260,719 Accumulated impairment charges (174,244 ) Balance at June 30, 2015 $ 86,475
Summary of intangible assets	Intangible assets consisted of the following: December 31, 2014 June 30, 2015 Gross Carrying Amount Accumulated Amortization Intangible Assets, net Gross Carrying Amount Accumulated Amortization Intangible Assets, net Amortizing intangible assets: Customer contracts $ 162,089 $ (93,617 ) $ 68,472 $ 175,864 $ (97,485 ) $ 78,379 Other 26,241 (21,758 ) 4,483 37,341 (22,414 ) 14,927 Total amortizing intangible assets $ 188,330 $ (115,375 ) $ 72,955 $ 213,205 $ (119,899 ) $ 93,306 Intangible assets not subject to amortization 42,975 36,305 Total other intangible assets $ 115,930 $ 129,611
Estimated annual amortization expense	Estimated annual amortization expense for each of the fiscal years ending December 31, is presented below: 2015 $ 8,875 2016 7,930 2017 7,491 2018 7,131 2019 6,647 Thereafter 59,756

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Other Accrued Liabilities [Abstract]
Components of other accrued liabilities	Other accrued liabilities consisted of the following: December 31, 2014 June 30, 2015 Accrued systems rental and maintenance costs $ 1,586 $ 2,457 Accrued site rental fees 992 940 Accrued property and sales taxes payable 9,276 9,973 Accrued self-insurance expense 2,276 2,657 Deferred gain on sale of equipment 312 312 Other accrued expenses 12,100 14,132 Total $ 26,542 $ 30,471

Long-Term Debt and Senior Sub28

Long-Term Debt and Senior Subordinated Credit Facility (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Components of long-term debt	Long-term debt consisted of the following: December 31, 2014 June 30, 2015 Term loan facility $ 482,825 $ 505,474 Discount on term loan facility (2,156 ) (2,074 ) Revolving credit facility 2,000 — Equipment debt 24,620 39,748 Long-term debt, including current portion 507,289 543,148 Less current portion 15,512 22,484 Long-term debt $ 491,777 $ 520,664

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2015
Summary of Derivative Instruments [Abstract]
Effect of Derivative Instruments on the Statement of Operations	The Effect of Designated Derivative Instruments on the Statement of Operations For the Quarter Ended June 30, 2014 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (375 ) Interest expense and other, net $ 8 Interest expense and other, net $ — The Effect of Designated Derivative Instruments on the Statement of Operations For the Six Months Ended June 30, 2014 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (478 ) Interest expense and other, net $ (126 ) Interest expense and other, net $ (2 ) The Effect of Designated Derivative Instruments on the Statement of Operations For the Quarter Ended June 30, 2015 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (19 ) Interest expense and other, net $ 5 Interest expense and other, net $ — The Effect of Designated Derivative Instruments on the Statement of Operations For the Six Months Ended June 30, 2015 Derivatives in Cash Flow Hedging Relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion) Interest rate contracts $ (208 ) Interest expense and other, net $ 16 Interest expense and other, net $ 1

Earnings Per Common Share (Tabl

Earnings Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Computation of basic and diluted loss per share	The following table sets forth the computation of basic and diluted earnings per share: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Numerator: Net income (loss) attributable to Alliance HealthCare Services, Inc. $ 2,784 $ (1,961 ) $ 4,715 $ (210 ) Denominator: Weighted-average shares-basic 10,671 10,715 10,669 10,714 Effect of dilutive securities: Employee stock options 183 121 203 125 Weighted-average shares-diluted 10,854 10,836 10,872 10,839 Income (loss) per common share attributable to Alliance HealthCare Services, Inc.: Basic $ 0.26 $ (0.18 ) $ 0.44 $ (0.02 ) Diluted $ 0.26 $ (0.18 ) $ 0.43 $ (0.02 ) Stock options excluded from the computation of diluted per share amounts: Weighted-average shares for which the exercise price exceeds average market price of common stock 132 394 134 335 Average exercise price per share that exceeds average market price of common stock $ 44.22 $ 30.15 $ 44.25 $ 31.57

Investments in Unconsolidated31

Investments in Unconsolidated Investees (Tables)	6 Months Ended
	Jun. 30, 2015
Alliance-HNI, LLC and Subsidiaries
Schedule Of Equity Method Investments [Line Items]
Schedule of financial data of unconsolidated investees, Balance Sheet Data	Set forth below are certain financial data for Alliance-HNI, LLC and Subsidiaries, one of the Company’s unconsolidated investees as of: December 31, 2014 June 30, 2015 Balance Sheet Data: Current assets $ 4,721 $ 4,319 Noncurrent assets 9,257 8,605 Current liabilities 2,773 2,513 Noncurrent liabilities 3,272 2,657
Schedule of financial data of unconsolidated investees, Combined Operating Results	Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Operating Results: Revenues $ 4,225 $ 4,237 $ 8,331 $ 8,401 Expenses 2,266 2,201 4,821 4,605 Net income 1,959 2,036 3,510 3,796 Earnings from unconsolidated investee 979 1,018 1,755 1,898
Unconsolidated Investees, Including Alliance-HNI, LLC and Subsidiaries and Austin Cyberknife
Schedule Of Equity Method Investments [Line Items]
Schedule of financial data of unconsolidated investees, Balance Sheet Data	Set forth below are certain financial data for the aggregate of the Company’s unconsolidated investees, including Alliance-HNI, LLC and Subsidiaries as of: December 31, 2014 June 30, 2015 Balance Sheet Data: Current assets $ 8,687 $ 6,992 Noncurrent assets 10,108 9,182 Current liabilities 3,760 3,477 Noncurrent liabilities 3,395 2,693
Schedule of financial data of unconsolidated investees, Combined Operating Results	Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Combined Operating Results: Revenues $ 6,765 $ 6,469 $ 13,196 $ 13,106 Expenses 3,210 2,920 6,745 6,256 Net income 3,555 3,549 6,451 6,850 Earnings from unconsolidated investees 1,242 1,292 2,240 2,455

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Summary of stockholders' deficit, including noncontrolling interest	The following table summarizes consolidated stockholders’ deficit, including noncontrolling interest. Additional Accumulated Stockholders’ Equity (Deficit) Attributable to Total Common Stock Treasury Stock Paid-In Comprehensive Accumulated Alliance HealthCare Noncontrolling Stockholders’ Shares Amount Shares Amount Capital Income (Loss) Deficit Services, Inc. Interest Deficit Balance at January 1, 2015 10,713,658 $ 107 (157,973 ) $ (3,138 ) $ 27,653 $ (351 ) $ (194,091 ) $ (169,820 ) $ 58,340 $ (111,480 ) Exercise of stock options 2,515 — — — 25 — — 25 — 25 Purchase of treasury stock — — — — — — — — — — Share-based payment — — — — 819 — — 819 — 819 Share-based payment income tax benefit — — — — (82 ) — — (82 ) — (82 ) Unrealized loss on hedging transaction, net of tax — — — — — (141 ) — (141 ) — (141 ) Net investments in subsidiaries — — — — — — — — 12,246 12,246 Net income (loss) — — — — — — (210 ) (210 ) 9,250 9,040 Balance at June 30, 2015 10,716,173 $ 107 (157,973 ) $ (3,138 ) $ 28,415 $ (492 ) $ (194,301 ) $ (169,409 ) $ 79,836 $ (89,573 )

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Summary of revenue by segment	The following table summarizes the Company’s revenue by segment: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Revenue Radiology $ 87,297 $ 84,994 $ 171,935 $ 166,381 Radiation Oncology 23,941 25,330 44,668 49,516 Corporate / Other — 8,180 — 12,036 Total $ 111,238 $ 118,504 $ 216,603 $ 227,933 The following are components of revenue: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Revenue MRI $ 45,637 $ 45,249 $ 89,822 $ 88,136 PET/CT 34,178 32,594 67,547 64,144 Radiation Oncology 23,941 25,330 44,668 49,516 Other radiology 7,482 7,151 14,566 14,101 Corporate / Other — 8,180 — 12,036 Total $ 111,238 $ 118,504 $ 216,603 $ 227,933
Summary of segment income	The following table summarizes the Company’s segment income (loss): Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Segment income (loss) Radiology $ 33,248 $ 28,419 $ 64,257 $ 54,793 Radiation Oncology 11,167 12,581 20,490 24,344 Corporate / Other (7,746 ) (6,985 ) (15,126 ) (15,006 ) Total $ 36,669 $ 34,015 $ 69,621 $ 64,131
Reconciliation of Net loss to total segment income	The reconciliation of net income (loss) to total segment income is shown below: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Net income (loss) attributable to Alliance HealthCare Services, Inc. $ 2,784 $ (1,961 ) $ 4,715 $ (210 ) Income tax expense (benefit) 1,802 (1,366 ) 3,309 206 Interest expense and other, net 6,124 6,904 12,362 12,922 Amortization expense 1,957 2,495 3,909 4,530 Depreciation expense 14,274 12,072 30,069 23,705 Share-based payment (included in selling, general and administrative expenses) 376 430 710 819 Severance and related costs 1,727 195 1,860 454 Noncontrolling interest in subsidiaries 4,036 4,903 7,085 9,250 Restructuring charges (Note 2) 1,563 236 2,455 491 Transaction costs 937 1,113 939 1,532 Impairment charges 236 6,670 236 6,746 Legal settlements 822 1,543 1,621 2,903 Other non-cash charges (included in other income and expense, net) 31 781 351 783 Total segment income $ 36,669 $ 34,015 $ 69,621 $ 64,131
Summary of net income (loss) by segment	The following table summarizes the Company’s net income (loss) by segment: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Net income (loss) Radiology $ 20,623 $ 17,937 $ 37,817 $ 34,934 Radiation Oncology 4,642 (1,629 ) 8,068 3,395 Corporate / Other (22,481 ) (18,269 ) (41,170 ) (38,539 ) Total $ 2,784 $ (1,961 ) $ 4,715 $ (210 )
Summary of Company's identifiable assets by segment	The following table summarizes the Company’s identifiable assets by segment: As of December 31, 2014 As of June 30, 2015 Identifiable assets Radiology $ 229,141 $ 238,810 Radiation Oncology 182,880 180,990 Corporate / Other 88,864 146,616 Total $ 500,885 $ 566,416
Summary of company's goodwill by segment	The following table summarizes the Company’s goodwill by segment: Radiology Radiation Oncology Corporate / Other Total Balance at January 1, 2014 $ 42,166 $ 14,809 $ — $ 56,975 Goodwill acquired during the period — 6,889 — 6,889 Impairment charges — — — — Adjustments to goodwill during the period — — — — Balance at December 31, 2014 $ 42,166 $ 21,698 $ — $ 63,864 Goodwill acquired during the period — — 22,611 22,611 Impairment charges — — — — Adjustments to goodwill during the period — — — — Balance at June 30, 2015 $ 42,166 $ 21,698 $ 22,611 $ 86,475 Gross goodwill $ 196,508 $ 41,600 $ 22,611 $ 260,719 Accumulated impairment charges (154,342 ) (19,902 ) — (174,244 ) Balance at June 30, 2015 $ 42,166 $ 21,698 $ 22,611 $ 86,475
Schedule of cash used for capital expenditures, by segment	The following table summarizes the cash used for capital expenditures for the Radiology, Radiation Oncology and Corporate segments: Quarter Ended Six Months Ended June 30, June 30, 2014 2015 2014 2015 Cash used for capital expenditures Radiology $ 4,761 $ 5,865 $ 6,828 $ 12,695 Radiation Oncology 19 3,022 19 3,757 Corporate / Other 2,741 2,806 6,409 2,806

Transactions - Additional Infor

Transactions - Additional Information (Details) $ in Thousands	Feb. 17, 2015USD ($)center	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 236	$ 1,563	$ 491	$ 2,455
Goodwill		86,475		86,475		$ 63,864	$ 56,975
Revenues		118,504	111,238	227,933	216,603
Net income (loss) attributable to Alliance HealthCare Services, Inc.		(1,961)	2,784	(210)	4,715
The Pain Center of Arizona, PC
Restructuring Cost and Reserve [Line Items]
Percentage of voting interests acquired	59.00%
Number of locations operated by entity | center	12
Percentage of voting interests acquired before dilution	60.00%
Payments to acquire businesses, gross	$ 23,630
Cash received	691
Accounts receivable extinguishment, related parties	3,071
Goodwill	22,611
Identifiable intangible assets	$ 24,600
Useful life	20 years
Weighted average useful life	15 years
Noncontrolling interest, fair value	$ 20,598
Revenues		8,167		12,023
Net income (loss) attributable to Alliance HealthCare Services, Inc.		20		$ 291
Contingent consideration performance period (in months)				12 months
Contingent consideration		$ 1,800		$ 1,800
The Pain Center of Arizona, PC | Physician referral network intangible assets
Restructuring Cost and Reserve [Line Items]
Identifiable intangible assets	13,500
The Pain Center of Arizona, PC | Trademarks
Restructuring Cost and Reserve [Line Items]
Identifiable intangible assets	$ 11,100
Medical Practice Innovations, Inc.
Restructuring Cost and Reserve [Line Items]
Percentage of voting interests acquired	50.00%
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges				95	1,640
Severance and related costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 1,860	454
Cost of revenues, excluding depreciation and amortization
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 396	$ 815

Transactions - Recognized Ident

Transactions - Recognized Identifiable Assets and Liabilities (Details) - USD ($) $ in Thousands	Feb. 17, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Goodwill		$ 86,475	$ 63,864	$ 56,975
The Pain Center of Arizona, PC
Business Acquisition [Line Items]
Cash received	$ 691
Accounts receivable, net	4,440
Equipment, net	3,346
Other assets	416
Goodwill	22,611
Identifiable intangible assets	24,600
Debt	(2,781)
Other liabilities	(3,532)
Noncontrolling interest	(20,598)
Total consideration	$ 29,193

Share-Based Payment - Weighted

Share-Based Payment - Weighted Average Assumptions for Fair Value of Stock Options (Details)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Weighted average assumptions for stock option awards
Risk free interest rate	1.65%	1.83%
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	65.20%	66.30%
Average expected life (in years)	6 years	6 years

Share-Based Payment - Stock Opt

Share-Based Payment - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Summary of stock option activity
Begining balance (shares)	633,898
Granted (shares)	83,514
Exercised (shares)	(2,515)	(67,657)
Canceled (shares)	(28,117)
Ending balance (shares)	686,780
Vested and expected to vest (shares)	662,238
Exercisable (shares)	488,809
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Beginning balance, weighted-average exercise price (dollars per share)	$ 21.39
Granted, weighted-average exercise price (dollars per share)	23.91
Exercised, weighted-average exercise price (dollars per share)	10.12
Canceled, weighted-average exercise price (dollars per share)	55.81
Ending balance, weighted-average exercise price (dollars per share)	20.35
Vested and expected to vest, weighted-average exercise price (dollars per share)	20.18
Exercisable, weighted-average exercise price (dollars per share)	$ 18.14
Outstanding, weighted-average remaining contractual term (in years)	6 years 6 days
Vested and expected to vest, weighted-average remaining contractual term (in years)	5 years 11 months 8 days
Exercisable, weighted-average remaining contractual term (in years)	5 years 2 months
Outstanding, aggregate intrinsic value	$ 3,482
Vested and expected to vest, aggregate intrinsic value	3,476
Exercisable, aggregate intrinsic value	$ 3,393

Share-Based Payment - Unvested

Share-Based Payment - Unvested Stock Activity (Details) - 6 months ended Jun. 30, 2015 - $ / shares	Total
Unvested stock option
Summary of unvested stock option activity
Beginning balance, unvested shares (shares)	197,899
Granted, unvested share (shares)	83,514
Vested, unvested share (shares)	(78,825)
Canceled, unvested share (shares)	(4,617)
Ending balance, unvested shares (shares)	197,971
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Beginning balance, unvested shares, weighted-average grant-date fair value (dollars per share)	$ 12.13
Granted, unvested shares, weighted-average grant-date fair value (dollars per share)	14.25
Vested, unvested shares, weighted-average grant-date fair value (dollars per share)	6.08
Canceled, unvested shares, weighted-average grant-date fair value (dollars per share)	15.35
Ending balance, unvested shares, weighted-average grant-date fair value (dollars per share)	$ 15.40
Restricted stock
Summary of unvested stock option activity
Beginning balance, unvested shares (shares)	32,959
Vested, unvested share (shares)	0
Canceled, unvested share (shares)	0
Ending balance, unvested shares (shares)	32,959
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Beginning balance, unvested shares, weighted-average grant-date fair value (dollars per share)	$ 20.99
Vested, unvested shares, weighted-average grant-date fair value (dollars per share)	0
Canceled, unvested shares, weighted-average grant-date fair value (dollars per share)	0
Ending balance, unvested shares, weighted-average grant-date fair value (dollars per share)	$ 20.99
Employees | Restricted stock
Summary of unvested stock option activity
Granted, unvested share (shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Granted, unvested shares, weighted-average grant-date fair value (dollars per share)	$ 0
Non-employee directors | Restricted stock
Summary of unvested stock option activity
Granted, unvested share (shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Granted, unvested shares, weighted-average grant-date fair value (dollars per share)	$ 0

Share-Based Payment - Textual (

Share-Based Payment - Textual (Details) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Sep. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 1999
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares available for options and awards (shares)		477,060					2,205,000
Options term (years)		10 years
Options accelerated due to employment agreements vesting (shares)		0		0
Weighted average grant date fair value (dollars per share)		$ 14.25	$ 17.56
Stock options exercised (shares)		2,515	67,657
Total unrecognized fair value related to unvested stock options		$ 2,046,000
Recognized weighted-average period (years)		2 years 25 days
Total fair value of shares vested		$ 479,000	$ 469,000
Non-Employee Director Serving as Member of Audit Committee
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Noninterest expense directors fees				$ 15,000
Non-Employee Director Serving as Chairman of Audit Committee
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Noninterest expense directors fees				30,000
Non-Employee Director Serving As Member of Nominating Committee, Compensation Committee, and Strategy and Finance Committee
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Noninterest expense directors fees				5,000
Directors' Deferred Compensation Plan | Non-employee directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Noninterest expense directors fees		40,000		$ 40,000
Directors' Deferred Compensation Plan | Unaffiliated directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Noninterest expense directors fees		140,000
Fair value of shares issued		$ 140,000
Time option | 1999 Equity Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Subsequent stock options, vesting after one year (percent)		5.00%
Subsequent stock options, vesting after two year (percent)		20.00%
Subsequent stock options, vesting after three year (percent)		25.00%
Subsequent stock options, vesting after four year (percent)		25.00%
Subsequent stock options, vesting after five year (percent)		25.00%
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)					1 year	3 years
Options, typically vesting each year from the date of grant (percent)						33.30%
Share-based payment		$ 344,000	$ 245,000
Restricted Stock Awards | Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized fair value related to unvested stock options		$ 0
Non-option equity instruments, granted			0
Number of awards to non-employees (shares)		0
Restricted Stock Awards | Non-employee directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of awards to non-employees (shares)		0
Restricted Stock Awards | Unaffiliated directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)					1 year
Total unrecognized fair value related to unvested stock options		$ 345,000
Recognized weighted-average period (years)		6 months
Period in force proceeding grant date		15 days
Restricted Stock Awards | Board of Directors Chairman
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of shares issued		$ 138,000
Period after resignation in which entitlement is valid		24 months
Requisite service period		1 year
Restricted Stock Awards | Cliff vest after one year
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)						1 year
Restricted Stock Units (RSUs) | Executive Management
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of awards to non-employees (shares)	25,000
Minimum market price that must be achieved		$ 40
Duration of minimum market price		10 days
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)		3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period (years)		4 years

Fair Value of Financial Instr40

Fair Value of Financial Instruments - Estimated Fair Value of Financial Instruments (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Estimated fair values of financial instruments
Cash and cash equivalents	$ 43,399	$ 33,033
Contingent consideration	1,800
Carrying Value
Estimated fair values of financial instruments
Cash and cash equivalents	43,399	33,033
Fixed-rate debt	24,154	13,015
Variable-rate debt	518,994	494,274
Contingent consideration	1,800	0
Derivative instruments - asset position	11	228
Derivative instruments - liability position	41	46
Fair Value
Estimated fair values of financial instruments
Cash and cash equivalents	43,399	33,033
Fixed-rate debt	23,774	13,878
Variable-rate debt	518,122	494,354
Contingent consideration	1,800	0
Derivative instruments - asset position	11	228
Derivative instruments - liability position	$ 41	$ 46

Fair Value of Financial Instr41

Fair Value of Financial Instruments - Summary of Valuation of Financial Instruments Reported at Fair Value on a Recurring Basis by Pricing Level (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Financial instruments reported at fair value on a recurring basis
Impairment charges	$ 6,670	$ 236	$ 6,746	$ 236
Recurring basis
Financial instruments reported at fair value on a recurring basis
Cash and cash equivalents	43,399		43,399		$ 33,033
Contingent consideration related to acquisition	1,800		1,800
Recurring basis | Interest rate contracts
Financial instruments reported at fair value on a recurring basis
Interest rate contracts - asset position	11		11		228
Interest rate contracts - liability position	41		41		46
Recurring basis | Quoted market prices in active markets (Level 1)
Financial instruments reported at fair value on a recurring basis
Cash and cash equivalents	43,399		43,399		33,033
Contingent consideration related to acquisition	0		0
Recurring basis | Quoted market prices in active markets (Level 1) | Interest rate contracts
Financial instruments reported at fair value on a recurring basis
Interest rate contracts - asset position	0		0
Interest rate contracts - liability position	0		0		0
Recurring basis | Significant other observable inputs (Level 2)
Financial instruments reported at fair value on a recurring basis
Cash and cash equivalents	0		0		0
Contingent consideration related to acquisition	0		0
Recurring basis | Significant other observable inputs (Level 2) | Interest rate contracts
Financial instruments reported at fair value on a recurring basis
Interest rate contracts - asset position	11		11		228
Interest rate contracts - liability position	41		41		46
Recurring basis | Significant unobservable inputs (Level 3)
Financial instruments reported at fair value on a recurring basis
Cash and cash equivalents	0		0		0
Contingent consideration related to acquisition	1,800		1,800
Recurring basis | Significant unobservable inputs (Level 3) | Interest rate contracts
Financial instruments reported at fair value on a recurring basis
Interest rate contracts - asset position	0		0
Interest rate contracts - liability position	0		$ 0		$ 0
Radiation Oncology
Financial instruments reported at fair value on a recurring basis
Impairment charges	$ 6,700

Goodwill and Intangible Asset42

Goodwill and Intangible Assets - Goodwill Rollforward (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Changes in the Carrying Amount of Goodwill
Beginning balance	$ 63,864	$ 56,975
Goodwill acquired during the period	22,611	6,889
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	86,475	$ 63,864
Gross goodwill	260,719
Accumulated impairment charges	$ (174,244)

Goodwill and Intangible Asset43

Goodwill and Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Amortizing intangible assets:
Gross Carrying Amount	$ 213,205	$ 188,330
Accumulated Amortization	(119,899)	(115,375)
Intangible Assets, net	93,306	72,955
Intangible assets not subject to amortization	36,305	42,975
Total other intangible assets	129,611	115,930
Customer contracts
Amortizing intangible assets:
Gross Carrying Amount	175,864	162,089
Accumulated Amortization	(97,485)	(93,617)
Intangible Assets, net	78,379	68,472
Other
Amortizing intangible assets:
Gross Carrying Amount	37,341	26,241
Accumulated Amortization	(22,414)	(21,758)
Intangible Assets, net	$ 14,927	$ 4,483

Goodwill and Intangible Asset44

Goodwill and Intangible Assets - Estimated Annual Amortization Expense (Details) $ in Thousands	Jun. 30, 2015USD ($)
Estimated annual amortization expense
2,015	$ 8,875
2,016	7,930
2,017	7,491
2,018	7,131
2,019	6,647
Thereafter	$ 59,756

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Textual (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Goodwill and Intangible Assets (Textual) [Abstract]
Impairment charges	$ 6,670	$ 236	$ 6,746	$ 236
Amortization expense	2,495	$ 1,957	$ 4,530	$ 3,909
Customer contracts
Goodwill and Intangible Assets (Textual) [Abstract]
Weighted-average estimated useful life of amortization intangible assets (years)			15 years
Other intangible assets
Goodwill and Intangible Assets (Textual) [Abstract]
Weighted-average estimated useful life of amortization intangible assets (years)			6 years
Radiation Oncology
Goodwill and Intangible Assets (Textual) [Abstract]
Impairment charges	$ 6,700

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Components of other accrued liabilities
Accrued systems rental and maintenance costs	$ 2,457	$ 1,586
Accrued site rental fees	940	992
Accrued property and sales taxes payable	9,973	9,276
Accrued self-insurance expense	2,657	2,276
Deferred gain on sale of equipment	312	312
Other accrued expenses	14,132	12,100
Total	$ 30,471	$ 26,542

Long-Term Debt and Senior Sub47

Long-Term Debt and Senior Subordinated Credit Facility - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt, including current portion	$ 543,148	$ 507,289
Current portion of long-term debt	22,484	15,512
Long-term debt	520,664	491,777
Term Loan Facility
Debt Instrument [Line Items]
Long-term debt, gross	505,474	482,825
Discount on term loan facility	(2,074)	(2,156)
Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility	0	2,000
Equipment Debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 39,748	$ 24,620

Long-Term Debt and Senior Sub48

Long-Term Debt and Senior Subordinated Credit Facility - Additional Information (Details)	Oct. 11, 2013USD ($)	Jul. 03, 2013USD ($)	Jun. 03, 2013USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2013USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 19, 2015USD ($)	Dec. 02, 2013USD ($)	Dec. 31, 2009	Dec. 31, 2004
Debt Instrument [Line Items]
Repayments of long-term debt						$ 7,351,000	$ 2,450,000
Minimum
Debt Instrument [Line Items]
Ownership percentage of subsidiaries				15.00%		15.00%
Maximum
Debt Instrument [Line Items]
Ownership percentage of subsidiaries				50.00%		50.00%
Term Loan Facility | Base Rate
Debt Instrument [Line Items]
Debt floor interest rate (percent)			4.25%
Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Debt floor interest rate (percent)			2.00%
Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Debt floor interest rate (percent)			5.25%
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Debt, leverage ratio			0.00375
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Debt, leverage ratio			0.005
New Credit Agreement
Debt Instrument [Line Items]
Ownership percentage of subsidiaries			50.00%
New Credit Agreement | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (percent)			1.00%
Debt description of variable rate basis			one-month LIBOR
New Credit Agreement | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percent)			0.50%
New Credit Agreement | Term Loan Facility
Debt Instrument [Line Items]
Term loan facility borrowing capacity		$ 340,000,000	$ 340,000,000
Debt term (years)			6 years
Repayments of long-term debt		$ 80,000,000
Revolving credit facility				$ 505,474,000		$ 505,474,000
Actual ratio of consolidated total debt to Consolidated Adjusted EBITDA				3.98		3.98
New Credit Agreement | Term Loan Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (percent)			3.25%
New Credit Agreement | Term Loan Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percent)			2.25%
New Credit Agreement | Term Loan Facility | Minimum
Debt Instrument [Line Items]
Covenant ratio of consolidated total debt to Consolidated Adjusted EBITDA, current year				4.30		4.30
New Credit Agreement | Term Loan Facility | Maximum
Debt Instrument [Line Items]
Debt, leverage ratio			3.25	4.85		4.85
Covenant ratio of consolidated total debt to Consolidated Adjusted EBITDA, current year				4.95		4.95
New Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Term loan facility borrowing capacity			$ 50,000,000
Debt term (years)			5 years
Revolving credit facility				$ 0		$ 0
New Credit Agreement | Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Debt floor interest rate (percent)			1.00%
New Credit Agreement | Revolving Credit Facility | Minimum | LIBOR
Debt Instrument [Line Items]
Debt, leverage ratio			0.03
New Credit Agreement | Revolving Credit Facility | Minimum | Base Rate
Debt Instrument [Line Items]
Debt, leverage ratio			0.02
New Credit Agreement | Revolving Credit Facility | Maximum | LIBOR
Debt Instrument [Line Items]
Debt, leverage ratio			0.0325
New Credit Agreement | Revolving Credit Facility | Maximum | Base Rate
Debt Instrument [Line Items]
Debt, leverage ratio			0.0225
New Credit Agreement | Letter of Credit
Debt Instrument [Line Items]
Term loan facility borrowing capacity			$ 20,000,000
New Credit Agreement | Uncommitted Incremental Loan Facility
Debt Instrument [Line Items]
Term loan facility borrowing capacity			100,000,000
New Credit Agreement | Delayed Draw
Debt Instrument [Line Items]
Term loan facility borrowing capacity			$ 80,000,000
Required draw period			30 days
Debt, quarterly payments at debt capacity			$ 1,050,000
Period quarterly amortization payments required			5 years 9 months
New Credit Agreement | Senior notes
Debt Instrument [Line Items]
Extinguishment of debt, amount			$ 190,000,000
Interest rate, stated percentage										8.00%
New Credit Agreement | Committed Incremental Term Loan
Debt Instrument [Line Items]
Term loan facility borrowing capacity				70,000,000		70,000,000			$ 70,000,000
Debt instrument, periodic payment						$ 1,050,000
New Credit Agreement | Committed Incremental Term Loan | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (percent)	3.25%
Debt floor interest rate (percent)	1.00%
New Credit Agreement | Committed Incremental Term Loan | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percent)	2.25%
Senior Notes, 7.25 Percent | Senior notes
Debt Instrument [Line Items]
Interest rate, stated percentage											7.25%
First Amendment to New Credit Agreement | Committed Incremental Term Loan
Debt Instrument [Line Items]
Term loan facility borrowing capacity	$ 70,000,000								$ 70,000,000
Percentage of principal amount funded	99.00%
Debt instrument, periodic payment					$ 1,225,000
Second Amendment to New Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Term loan facility borrowing capacity								$ 50,000
Second Amendment to New Credit Agreement | Committed Incremental Term Loan
Debt Instrument [Line Items]
Term loan facility borrowing capacity								$ 30,000
Percentage of principal amount funded	99.50%
Debt instrument, periodic payment				$ 1,300,000

Derivatives - Textual (Details)

Derivatives - Textual (Details) $ in Thousands	3 Months Ended			6 Months Ended
	Dec. 31, 2013USD ($)agreement	Jun. 30, 2011agreement	Mar. 31, 2010USD ($)agreement	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014	Mar. 31, 2013	Dec. 31, 2012
Interest Rate Cash Flow Hedges
Derivative [Line Items]
Variable bank rate debt				$ 257,075	$ 258,500
Variable rate debt as a percent of total debt (percent)				47.30%	50.90%
Expected reclassification from accumulated other comprehensive loss to interest expense and other, net				$ 351
Interest rate cap
Derivative [Line Items]
Derivative, notional amount	$ 250,000
Paid for cap purchase amortized as interest expense	$ 815
Interest rate agreement, basis spread on variable rate (percent)	2.50%
Interest rate cap | Interest Rate Cash Flow Hedges
Derivative [Line Items]
Number of agreements | agreement	5		3
Maturity			Feb. 1, 2014
Derivative, notional amount			$ 150,000
USR Swap one | Interest Rate Cash Flow Hedges
Derivative [Line Items]
Maturity		Oct. 1, 2015
Derivative, notional amount				349
Fixed rate of interest paid by the Company (percent)		5.71%
Recorded interest expense rate (percent)		8.71%
Underlying debt interest rate (percent)		3.00%
USR Swap two | Interest Rate Cash Flow Hedges
Derivative [Line Items]
Maturity		Apr. 1, 2014
Interest Rate Swap, Maturing December 2017
Derivative [Line Items]
Derivative, notional amount				2,717
Fixed rate of interest paid by the Company (percent)								3.75%
Recorded interest expense rate (percent)								3.75%
Interest rate agreement, basis spread on variable rate (percent)								2.50%
Interest Rate Swap, Maturing December 2017 | LIBOR
Derivative [Line Items]
Interest rate agreement, basis spread on variable rate (percent)								2.50%
Interest Rate Swap, Matures April 2018
Derivative [Line Items]
Derivative, notional amount				2,491
Fixed rate of interest paid by the Company (percent)							2.873%
Recorded interest expense rate (percent)							2.873%
Interest rate agreement, basis spread on variable rate (percent)							2.00%
Interest Rate Swap, Matures April 2018 | LIBOR
Derivative [Line Items]
Interest rate agreement, basis spread on variable rate (percent)							2.00%
Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount				$ 1,519
Interest rate agreement, basis spread on variable rate (percent)						1.34%
Interest Rate Swap | Interest Rate Cash Flow Hedges
Derivative [Line Items]
Number of agreements | agreement		2

Derivatives - Income Statement

Derivatives - Income Statement Impact (Details) - Designated Derivative Instruments - Derivatives in Cash Flow Hedging Relationships - Interest rate contracts - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Effect of Derivative Instruments on Statement of Operations
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	$ (19)	$ (375)	$ (208)	$ (478)
Interest expense and other, net
Effect of Derivative Instruments on Statement of Operations
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	5	8	16	(126)
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion)	$ 0	$ 0	$ 1	$ (2)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (1,366)	$ 1,802	$ 206	$ 3,309
Income tax benefit (percentage)	41.00%	39.30%	(5725.00%)	41.20%
Share-based compensation cost, amount			$ 204
Net income (loss) attributable to Alliance HealthCare Services, Inc.	$ 1,961	$ (2,784)	210	$ (4,715)
Unrecognized tax benefits related to various federal and state income tax matters	301		301
Tax-effected amount that would reduce the company's effective income tax rate if recognized	256		256
Accrued interest and penalties related to unrecognized tax benefits	$ 16		$ 16

Earnings Per Common Share (Deta

Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator [Abstract]
Net income (loss) attributable to Alliance HealthCare Services, Inc.	$ (1,961)	$ 2,784	$ (210)	$ 4,715
Denominator [Abstract]
Weighted-average shares-basic (shares)	10,715	10,671	10,714	10,669
Effect of dilutive securities:
Employee stock options (shares)	121	183	125	203
Weighted-average shares-diluted (shares)	10,836	10,854	10,839	10,872
Income (loss) per common share attributable to Alliance HealthCare Services, Inc.:
Basic (dollars per share)	$ (0.18)	$ 0.26	$ (0.02)	$ 0.44
Diluted (dollars per share)	$ (0.18)	$ 0.26	$ (0.02)	$ 0.43
Stock options excluded from the computation of diluted per share amounts:
Weighted-average shares for which exercise price exceeds average market price of common stock (shares)	394	132	335	134
Average exercise price per share that exceeds average market price of common stock (dollars per share)	$ 30.15	$ 44.22	$ 31.57	$ 44.25

Commitments and Contingencies (

Commitments and Contingencies (Details)	Jul. 14, 2015Count	Feb. 10, 2015Count	Jun. 14, 2013company	Jun. 30, 2015USD ($)
Loss Contingencies [Line Items]
Liability related to guarantees and indemnities | $				$ 0
HVMA
Loss Contingencies [Line Items]
Number of companies involved in lawsuit | company			2
Dr. Barry Michael Driver
Loss Contingencies [Line Items]
Number of counts in claim		4
Dr. Barry Michael Driver | Subsequent Event
Loss Contingencies [Line Items]
Number of counts dismissed	3

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)	Jun. 03, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 02, 2013	Jul. 03, 2013	Apr. 16, 2007
Related Party Transaction [Line Items]
Shares purchased by Oaktree and MTS (shares)								4,900,301
Percentage of outstanding stock owned by Oaktree and MTS (percent)		50.70%		50.70%				49.70%
Revenues from management agreements with unconsolidated equity investees		$ 2,209,000	$ 2,241,000	$ 4,587,000	$ 4,562,000
Amounts of the revenues and expenses		1,782,000	$ 1,783,000	3,729,000	$ 3,687,000
New Credit Agreement | Term Loan Facility
Related Party Transaction [Line Items]
Debt amount funded		505,474,000		505,474,000
Term loan facility borrowing capacity	$ 340,000,000						$ 340,000,000
Debt term (years)	6 years
New Credit Agreement | Delayed Draw
Related Party Transaction [Line Items]
Term loan facility borrowing capacity	$ 80,000,000
New Credit Agreement | Committed Incremental Term Loan
Related Party Transaction [Line Items]
Term loan facility borrowing capacity		70,000,000		70,000,000		$ 70,000,000
New Credit Agreement | Oaktree | Term Loan Facility
Related Party Transaction [Line Items]
Debt amount funded	40,476,000
Term loan facility borrowing capacity	$ 340,000,000
Debt term (years)	6 years
New Credit Agreement | Oaktree | Delayed Draw
Related Party Transaction [Line Items]
Debt amount funded							9,524,000
Term loan facility borrowing capacity							$ 80,000,000
New Credit Agreement | Oaktree | Committed Incremental Term Loan
Related Party Transaction [Line Items]
Term loan facility borrowing capacity		$ 10,000,000		$ 10,000,000

Investments in Unconsolidated55

Investments in Unconsolidated Investees - Textual (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)center	Jun. 30, 2015investee
Schedule Of Equity Method Investments [Line Items]
Number of unconsolidated entities with direct ownership (investee) | investee		3
Impairment of equity method investment	$ 236
Number of cancer centers closed | center	1
Minimum
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership from investees (percent)		15.00%
Maximum
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership from investees (percent)		50.00%

Investments in Unconsolidated56

Investments in Unconsolidated Investees - Balance Sheet Data (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Alliance-HNI, LLC and Subsidiaries
Schedule of financial data of unconsolidated investees, Balance Sheet Data
Current assets	$ 4,319	$ 4,721
Noncurrent assets	8,605	9,257
Current liabilities	2,513	2,773
Noncurrent liabilities	2,657	3,272
Unconsolidated Investees, Including Alliance-HNI, LLC and Subsidiaries and Austin Cyberknife
Schedule of financial data of unconsolidated investees, Balance Sheet Data
Current assets	6,992	8,687
Noncurrent assets	9,182	10,108
Current liabilities	3,477	3,760
Noncurrent liabilities	$ 2,693	$ 3,395

Investments in Unconsolidated57

Investments in Unconsolidated Investees - Combined Operating Results (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Schedule of financial data of unconsolidated investees, Combined Operating Results
Earnings from unconsolidated investee	$ 1,292	$ 1,242	$ 2,455	$ 2,240
Alliance-HNI, LLC and Subsidiaries
Schedule of financial data of unconsolidated investees, Combined Operating Results
Revenues	4,237	4,225	8,401	8,331
Expenses	2,201	2,266	4,605	4,821
Net income	2,036	1,959	3,796	3,510
Earnings from unconsolidated investee	1,018	979	1,898	1,755
Unconsolidated Investees, Including Alliance-HNI, LLC and Subsidiaries and Austin Cyberknife
Schedule of financial data of unconsolidated investees, Combined Operating Results
Revenues	6,469	6,765	13,106	13,196
Expenses	2,920	3,210	6,256	6,745
Net income	3,549	3,555	6,850	6,451
Earnings from unconsolidated investee	$ 1,292	$ 1,242	$ 2,455	$ 2,240

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance			$ (111,480)
Exercise of stock options (shares)			2,515	67,657
Exercise of stock options			$ 25
Share-based payment			819
Share-based payment income tax benefit			(82)
Unrealized loss on hedging transaction, net of tax			(141)
Net investments in subsidiaries			12,246
Net income (loss)	$ 2,942	$ 6,820	9,040	$ 11,800
Ending balance	$ (89,573)		$ (89,573)
Common Stock
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance (shares)			10,713,658
Beginning balance			$ 107
Exercise of stock options (shares)			2,515
Ending balance (shares)	10,716,173		10,716,173
Ending balance	$ 107		$ 107
Treasury Stock
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance (shares)			157,973
Beginning balance			$ (3,138)
Ending balance (shares)	157,973		157,973
Ending balance	$ (3,138)		$ (3,138)
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance			27,653
Exercise of stock options			25
Share-based payment			819
Share-based payment income tax benefit			(82)
Ending balance	28,415		28,415
Accumulated Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance			(351)
Unrealized loss on hedging transaction, net of tax			(141)
Ending balance	(492)		(492)
Accumulated Deficit
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance			(194,091)
Net income (loss)			(210)
Ending balance	(194,301)		(194,301)
Alliance HealthCare Services, Inc.
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance			(169,820)
Exercise of stock options			25
Share-based payment			819
Share-based payment income tax benefit			(82)
Unrealized loss on hedging transaction, net of tax			(141)
Net income (loss)			(210)
Ending balance	(169,409)		(169,409)
Noncontrolling Interest
Increase (Decrease) in Stockholders' Deficit [Roll Forward]
Beginning balance			58,340
Net investments in subsidiaries			12,246
Net income (loss)			9,250
Ending balance	$ 79,836		$ 79,836

Segment Information - Textual (

Segment Information - Textual (Details)	6 Months Ended
	Jun. 30, 2015segment
Segment Reporting [Abstract]
Number of operating segments (segment)	3
Number of reportable segments (segment)	2

Segment Information - Revenue b

Segment Information - Revenue by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Summary of revenue by segment
Revenue	$ 118,504	$ 111,238	$ 227,933	$ 216,603
Operating Segments | Radiology
Summary of revenue by segment
Revenue	84,994	87,297	166,381	171,935
Operating Segments | Radiation Oncology
Summary of revenue by segment
Revenue	25,330	23,941	49,516	44,668
Corporate, Non-Segment
Summary of revenue by segment
Revenue	$ 8,180	$ 0	$ 12,036	$ 0

Segment Information - Component

Segment Information - Components of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Summary of components of revenue
Revenue	$ 118,504	$ 111,238	$ 227,933	$ 216,603
Operating Segments | MRI
Summary of components of revenue
Revenue	45,249	45,637	88,136	89,822
Operating Segments | PET/CT
Summary of components of revenue
Revenue	32,594	34,178	64,144	67,547
Operating Segments | Other Radiology Revenue
Summary of components of revenue
Revenue	7,151	7,482	14,101	14,566
Corporate, Non-Segment
Summary of components of revenue
Revenue	$ 8,180	$ 0	$ 12,036	$ 0

Segment Information - Summary o

Segment Information - Summary of Segment Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Summary of segment income
Segment income	$ 34,015	$ 36,669	$ 64,131	$ 69,621
Operating Segments | Radiology
Summary of segment income
Segment income	28,419	33,248	54,793	64,257
Operating Segments | Radiation Oncology
Summary of segment income
Segment income	12,581	11,167	24,344	20,490
Corporate, Non-Segment
Summary of segment income
Segment income	$ (6,985)	$ (7,746)	$ (15,006)	$ (15,126)

Segment Information - Reconcili

Segment Information - Reconciliation of Net Loss to Segment Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Reconciliation of Net loss to total segment income
Net income (loss) attributable to Alliance HealthCare Services, Inc.	$ (1,961)	$ 2,784	$ (210)	$ 4,715
Income tax expense (benefit)	(1,366)	1,802	206	3,309
Interest expense and other, net	6,904	6,124	12,922	12,362
Amortization expense	2,495	1,957	4,530	3,909
Depreciation expense	12,072	14,274	23,705	30,069
Share-based payment (included in selling, general and administrative expenses)	430	376	819	710
Severance and related costs		1,727		1,860
Severance and related costs	195	1,727	454	1,860
Noncontrolling interest in subsidiaries	4,903	4,036	9,250	7,085
Restructuring charges	236	1,563	491	2,455
Transaction costs	1,113	937	1,532	939
Impairment charges	6,670	236	6,746	236
Legal settlements	1,543	822	2,903	1,621
Other non-cash charges (included in other income and expense, net)	781	31	783	351
Total segment income	$ 34,015	$ 36,669	$ 64,131	$ 69,621

Segment Information - Summary64

Segment Information - Summary of Net (Loss) Income by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Summary of net income (loss) by segment
Net income (loss) attributable to Alliance HealthCare Services, Inc.	$ (1,961)	$ 2,784	$ (210)	$ 4,715
Operating Segments | Radiology
Summary of net income (loss) by segment
Net income (loss) attributable to Alliance HealthCare Services, Inc.	17,937	20,623	34,934	37,817
Operating Segments | Radiation Oncology
Summary of net income (loss) by segment
Net income (loss) attributable to Alliance HealthCare Services, Inc.	(1,629)	4,642	3,395	8,068
Corporate, Non-Segment
Summary of net income (loss) by segment
Net income (loss) attributable to Alliance HealthCare Services, Inc.	$ (18,269)	$ (22,481)	$ (38,539)	$ (41,170)

Segment Information - Summary65

Segment Information - Summary of Identifiable Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Summary of Company's identifiable assets by segment
Identifiable assets	$ 566,416	$ 500,885
Operating Segments | Radiology
Summary of Company's identifiable assets by segment
Identifiable assets	238,810	229,141
Operating Segments | Radiation Oncology
Summary of Company's identifiable assets by segment
Identifiable assets	180,990	182,880
Corporate, Non-Segment
Summary of Company's identifiable assets by segment
Identifiable assets	$ 146,616	$ 88,864

Segment Information - Summary66

Segment Information - Summary of Goodwill by Segment (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Summary of goodwill by segment
Beginning balance	$ 63,864	$ 56,975
Goodwill acquired during the period	22,611	6,889
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	86,475	63,864
Gross goodwill	260,719
Accumulated impairment charges	(174,244)
Operating Segments | Radiology
Summary of goodwill by segment
Beginning balance	42,166	42,166
Goodwill acquired during the period	0	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	42,166	42,166
Gross goodwill	196,508
Accumulated impairment charges	(154,342)
Operating Segments | Radiation Oncology
Summary of goodwill by segment
Beginning balance	21,698	14,809
Goodwill acquired during the period	0	6,889
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	21,698	21,698
Gross goodwill	41,600
Accumulated impairment charges	(19,902)
Corporate, Non-Segment
Summary of goodwill by segment
Beginning balance	0	0
Goodwill acquired during the period	22,611	0
Impairment charges	0	0
Adjustments to goodwill during the period	0	0
Ending balance	22,611	$ 0
Gross goodwill	22,611
Accumulated impairment charges	$ 0

Segment Information - Summary67

Segment Information - Summary of Cash Used for Capital Expenditures by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Cash used for capital expenditures			$ 26,382	$ 13,256
Operating Segments | Radiology
Segment Reporting Information [Line Items]
Cash used for capital expenditures	$ 5,865	$ 4,761	12,695	6,828
Operating Segments | Radiation Oncology
Segment Reporting Information [Line Items]
Cash used for capital expenditures	3,022	0	3,757	19
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Cash used for capital expenditures	$ 2,806	$ 2,741	$ 2,806	$ 6,409